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Introduction 
Nonviral DNA delivery provides a mechanism to directly 
alter endogenous gene expression and cellular behavior 
with applications in functional genomics, tissue engineer-
ing, medical devices and gene therapy [1]. Because un-
aided delivery of naked plasmid DNA (pDNA) to cells has 
low efficacy, nonviral carriers are a common approach to 
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Abstract 
Background Design of efficient nonviral gene delivery systems is limited by the rudimentary understanding of specific 
molecules that facilitate transfection. 
Methods Polyplexes using 25-kDa polyethylenimine (PEI) and plasmid encoding green fluorescent protein (GFP) were 
delivered to HEK 293T cells. After treating cells with polyplexes, microarrays were used to identify endogenous genes 
differentially expressed between treated and untreated cells (2 h of exposure) or between flow-separated transfected 
cells (GFP+) and treated, untransfected cells (GFP–) at 8, 16 and 24 h after lipoplex treatment. Cell priming studies were 
conducted using pharmacologic agents to alter endogenous levels of the identified differentially expressed genes to 
determine effect on transfection levels. Differentially expressed genes in polyplex-mediated transfection were com-
pared with those differentially expressed in lipoplex transfection to identify DNA carrier-dependent molecular factors. 
Results Differentially expressed genes were RGS1, ARHGAP24, PDZD2, SNX24, GSN and IGF2BP1 after 2 h; RAP1A and 
ACTA1 after 8 h; RAP1A, WDR78 and ACTA1 after 16 h; and RAP1A, SCG5, ATF3, IREB2 and ACTA1 after 24 h. Pharma-
cologic studies altering endogenous levels for ARHGAP24, GSN, IGF2BP1, PDZD2 and RGS1 were able to increase or 
decrease transgene production. Comparing differentially expressed genes for polyplexes and lipoplexes, no common 
genes were identified at the 2-h time point, whereas, after the 8-h time point, RAP1A, ATF3 and HSPA6 were similarly 
expressed. SCG5 and PGAP1 were only upregulated in polyplex-transfected cells. 
Conclusions The identified genes and pharmacologic agents provide targets for improving transfection systems, al-
though polyplex or lipoplex dependencies must be considered.
Keywords GFP, HEK 293, LF2000, microarray analysis, nonviral gene delivery, PEI, temporal gene expression profile  
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enhance delivery. Nonviral carriers such as cationic poly-
mers (polyplexes) [2,3] and lipids (lipoplexes) [4–9] are 
used to electrostatically complex DNA to protect it against 
degradation and facilitate DNA transfer [10–12]. However, 
current nonviral DNA delivery systems are inefficient for 
therapeutic use [11,13–15] because our rudimentary un-
derstanding of the molecules and processes that facili-
tate nonviral gene delivery limits the design of efficient 
delivery systems. 
Previous studies have advanced the understanding 
of nonviral gene delivery, including particle tracking to 
identify extracellular [16–19] or intracellular [20–28] bar-
riers to DNA transfer, or microarray analysis to understand 
the toxicogenomic response of cells and tissues to non-
viral gene delivery systems [29]. Those particle tracking 
studies have identified compartments and components 
of the cell that interact with lipoplexes or polyplexes, at 
the same time as providing pharmacokinetic information 
on the movement of the complexes throughout the cell. 
Those data have been integrated into mathematical mod-
els to further our understanding of the gene transfer pro-
cess [30–33]. Similarly, previous microarray studies have 
provided global gene expression profiles in cells and tis-
sues exposed to cationic lipoplexes [29] or polyplexes [14] 
and identified specific genes involved in cytotoxicity and 
apoptosis [34], which can be dependent on the length of 
time of exposure to the DNA carrier, cell type, and DNA 
carrier [14,29,34]. These studies have been instrumental 
in providing information necessary for targeted physico-
chemical modification of the DNA carrier [31,35–39] and, 
although achieving promising in vitro and in vivo transfec-
tion from lipid and polymer DNA carriers [40], transfection 
still remains below desired levels. Those previous micro-
array studies were limited in that molecules that facilitate 
transfection were not identified (i.e. comparisons of gene 
profiles between treated and transfected cells to treated 
but untransfected cells were not made), even though it is 
the treated but untransfected cell population that limits 
the therapeutic efficacy and use of nonviral DNA delivery 
systems. A large gap in knowledge remains about mole-
cules that actively facilitate DNA transfer [41], which will 
have to be exploited in the design of enhanced gene de-
livery systems. 
To address the gap in knowledge concerning mecha-
nisms that facilitate transfection, we previously published 
studies where, 24 h after delivery of DNA complexes en-
coding the green fluorescent protein (GFP) transgene, we 
isolated human embryonic epithelial kidney (HEK 293T) 
cells that expressed the transgene (GFP+) and compared 
their gene expression profile to the treated-but- untrans-
fected cells (GFP–). In doing so, we identified specific 
genes and pathways utilized by transfected cells rela-
tive to untransfected cells and confirmed the ability of 
RAP1A and HSP6A to enhance lipoplex transfection [42] 
or RAP1A, SCG5, ACRC, ATF3, ACTA1 and IREB2 to en-
hance polyplex transfection [43]. Because those studies 
were performed at the 24-h time point when transgene 
expression is fully established, we now extend our ap-
proach in the present study for polyplexes by identifying 
genes at earlier time points because: (i) gene expression 
profiles have been shown to vary over time [44]; (ii) tar-
geting a single barrier or step in DNA transfer will proba-
bly not lead to a therapeutically relevant transfection sys-
tem [32]; and (iii) other genes and pathways largely remain 
unidentified that are implicated at earlier stages of trans-
fection (e.g. internalization, endosomal escape, nuclear lo-
calization, nuclear entry) [3,19,30,31,39,41,45–52]. 
As a first objective of the present study, we identified 
genes and pathways implicated at 2, 8, 16 and 24 h af-
ter delivery of GFP transgene to HEK 293T cells using a 
cationic polymer vector (polyethylenimine; PEI), whereas 
our other work focuses on the lipid vector (Lipofectamine 
2000; LF2000) [53]. PEI is a one of the most widely used 
polymer gene carriers because it transfects a broad range 
of cells and can be easily modified [54]. Relative to un-
treated cells, transcriptome profiling of HEK 293T cells 
at 2 h post-delivery of polyplexes was used to identify 
those endogenous genes that may act in response to 
treatment stress such as toxicity induced by the complex 
[13] or inherent intracellular defenses against foreign nu-
cleic acids [55]. Relative to GFP– cells, transcriptome pro-
filing was used to identify those endogenous genes used 
by transfected cells (GFP+) that may aid in overcom-
ing cellular barriers known to occur during DNA transfer 
[3,19,30,31,39,41,45–52] at 8, 16 and 24 h post-delivery of 
polyplexes. Events that typically take place 8 h after de-
livery of complexes to the cells include high rate of en-
dosomal escape [41,45], unpacking of pDNA from vector 
[45,46], some nuclear localization of complexes or pDNA 
[19,30,31,45,47], very small amounts of nuclear internaliza-
tion of complexes or pDNA [30,39,47] and very little pro-
duction of transgenic protein [30,48]. Events that typically 
take place 16 h after delivery of complexes to the cells 
include a high rate of nuclear localization of complexes 
or pDNA [19,30,47], continued nuclear internalization of 
complexes or pDNA [3,30,39,47] and continued produc-
tion of transgenic proteins [30,48]. Events that take place 
24 h after delivery of complexes to the cells include the 
continued nuclear internalization of pDNA [30,31,39,47], 
the highest synthesis of transgenic proteins [30,31,48] and 
mitosis (including distribution of transgenic proteins and 
pDNA to daughter cells) [47,49]. Therefore, the time points 
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chosen for the studies in the present study were selected 
to capture several key cellular events that occur through-
out the gene delivery process. We also ascertained the 
potential role of several of the identified genes as far as 
their ability to affect transfection by use of pharmacologic 
activators or inhibitors of the target endogenous gene. 
As a second objective of the present study, we compared 
those genes identified in the present study for polyplexes 
to those genes identified for lipoplexes [53]. Several dif-
ferent genes were expressed at each time point and may 
explain some of the mechanistic differences observed in 
transfection from the two nonviral gene delivery systems: 
internalization kinetics, mechanism of endosomal escape, 
and transfection levels [14,29–34,44,56–64]. The identifi-
cation of molecules and pathways that facilitate transfec-
tion as identified in the present study offers new targets 
for engineering enhanced transfection systems or for cell 
priming strategies for increased transfection. 
Materials and methods 
Cell culture and plasmid preparation 
HEK 293T cells (ATCC, Manassas, VA, USA) were cultured 
in T-75 flasks in Dulbecco’s modified Eagle’s medium 
containing 4.5 g/l glucose, supplemented with 10% fe-
tal bovine serum, 1mM sodium pyruvate, 100 units/ml 
of penicillin-streptomycin (all Gibco, Carlsbad, CA, USA) 
and maintained at 37°C in a humidified 5% CO2 atmo-
sphere. For seeding, cells were dissociated at confluence 
with 1mM ethylenediaminetetraacetic acid (EDTA) and vi-
able cells were counted using a hemocytometer and try-
pan blue dye exclusion assay. Plasmid pEGFP-LUC encodes 
both the enhanced green fluorescent protein (EGFP) and 
firefly luciferase protein (LUC) under the direction of a cy-
tomegalovirus promoter (Clontech, Mountain View, CA, 
USA), and was used for transfection experiments (see be-
low). Plasmid was purified from bacteria culture using Qia-
gen (Valencia, CA, USA) reagents and stored in Tris–EDTA 
buffer solution (10mM Tris, 1mM EDTA, pH 7.4) at –20°C. 
Transfection and sample isolation for microarray 
Cells were seeded at a density of 44.8×103 cells/cm2 into 
multiple T-75 flasks. After adherence (approximately 18 
h after seeding), polyplexes were formed using 25-kDa 
branched polyethylenimine (PEI; Sigma-Aldrich, St Louis, 
MO, USA). PEI was diluted in 1X Tris-buffered saline (TBS) 
and was added dropwise to pEGFPLuc diluted in 1X TBS 
at an N:P of 20 to deliver 0.25μg/cm2 pDNA to the cells. 
After forming at room temperature for 15 min, the poly-
plexes were delivered to the media above the cells. Those 
transfection conditions were optimal for high transfection 
(typically 50–70%) and low cytotoxicity with optimization 
performed as previously described [43]. The complexes re-
mained in contact with the cells for the duration of each 
experiment: 2, 8, 16 and 24h. After the incubation period 
of the polyplexes at each time point, cells were dissociated 
using 0.05% Trypsin-EDTA (except only EDTA for the 2-h 
condition) and suspended in 1X PBS at 2–5 million cells/
ml and placed on ice. For the 2-h time point, because very 
little GFP had been produced, untreated samples were 
obtained identically as were the treated samples except 
no polyplexes were delivered to the cells. For the 8-, 16- 
and 24-h time points, after dissociation, the treated cells 
were separated into transfected (GFP+) and untransfected 
(GFP–) pure cell populations using fluorescence activated 
cell sorting (FACS), as described previously [42]. Briefly, at 
8h, 16h, or 24h after addition of complexes, cells were dis-
sociated, counted, and concentrated in 1X PBS and placed 
on ice. For the 8-, 16- and 24-h time points, after disso-
ciation, the treated cells were separated into transfected 
(GFP+) and untransfected (GFP–) pure cell populations us-
ing fluorescence activated cell sorting (FACS), as described 
previously [45]. Briefly, at 8, 16 or 24 h after the addition of 
complexes, cells were dissociated, counted, and concen-
trated in 1X PBS and placed on ice, as described above. 
Flow cytometric analysis was performed using a B-D FAC-
SVantage SE three-laser, high speed cell sorter (University 
of Nebraska-Lincoln’s Center for Biotechnology Flow Cy-
tometry Core Facility) equipped with a 530/15nm SE la-
ser. A live gate was set on the GFP+ cell population in for-
ward scatter versus side scatter plot to remove cell debris 
or clumped cells from the sort. A minimum of 2×106 cells 
for each population (GFP+, GFP–) was collected. Cells were 
collected at each time point on three different days pro-
viding the following independent samples (n=3 for each 
sample): 2 h treated, 2 h untreated, 8 h GFP+, 8 h GFP–, 
16 h GFP+, 16 h GFP–, 24 h GFP+ and 24 h GFP– (for an 
overview of the experimental design, see Figure 1). RNA 
from each sample was then extracted, purified and hybrid-
ized to microarrays (see below). 
RNA extraction and microarray hybridization 
RNA extraction and quality check was performed as de-
scribed previously [42]. Briefly, after obtaining each sam-
ple (24 in total: three each for 2 h treated, 2 h untreated, 8 
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h GFP+, 8 h GFP–, 16 h GFP+, 16 h GFP–, 24 GFP+ and 24 
h GFP–; see also above and Figure 1), total RNA was TRIzol 
extracted and further purified using a Qiagen RNeasy col-
umn (Qiagen) to achieve a 260/280 ratio greater than 1.8 
on Nanodrop 2000 (Thermo Scientific, West Palm Beach, 
FL, USA). After quality assessment using an RNA 6000 
Nano LabChip on an Agilent BioAnalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA), purified RNA was re-
verse transcribed to cDNA and hybridized to Affymetrix 
GeneChip Human Genome U133 Plus 2.0 Arrays (Affyme-
trix, Santa Clara, CA, USA) overnight at 45°C, in accor-
dance with the manufacturer’s instructions. After strepta-
vidin-phycoerythrin conjugate staining, expression data 
were read with the GeneChip Scanner 3000 7G (Affyme-
trix) to obtain the expression data of over 47 000 tran-
scripts and variants annotated for all known genes of the 
human genome. Affymetrix GeneChip Operating Software 
(GCOS, version 1.3) was used for washing, scanning and 
basic data analysis, including calculation of absolute val-
ues and normalization of the data with respect to inter-
nal standards. 
Microarray and bioinformatics analyses 
Each microarray provides 11 independent measures of 
gene expression (n=11) for over 47 000 transcripts and 
variants annotated for all known genes of the human ge-
nome. Microarray expression data were background ad-
justed and normalized [65] and quality tested using R/
Bioconductor with AffyCoreTools library package with all 
arrays showing good hybridization quality, as described 
previously [42,43]. The gene expression data has been 
Figure 1. Overview of the experimental design (see Materials and methods). HEK 293T cells were seeded and allowed to become 
adherent (approximately 18 h). Then, lipoplexes were formed and delivered to adherent cells and allowed to remain in contact for 2, 
8, 16 or 24 h. At the 2-h time point, treated cells were harvested and RNA was extracted and hybridized to microarrays. The treated 
profile was compared with cells that underwent the same treatments, except no lipoplexes were delivered. At the 8-, 16- or 24-h time 
points, treated cells were FACS separated into GFP positive (GFP+; transfected) and GFP negative (GFP–; untransfected) cell popu-
lations and RNA was extracted and hybridized to microarrays. The process was repeated on separate days to achieve n=3 for each 
population at each time point.  
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deposited at the NCBI Gene Expression Omnibus (GEO) 
accession GSE59665. Differentially expressed genes be-
tween treated and untreated (2-h time point) or GFP+ and 
GFP– (8-, 16- and 24-h time points) were determined us-
ing a nonparametric mean variance smoothing method 
developed for R programming environment [66]. Micro-
array data for the 24-h time point were previously col-
lected and analyzed using linear models [42] and were 
downloaded from GEO accession GSE38422. Those micro-
arrays were again analyzed here, using the nonparamet-
ric smoothing method, which resulted in a larger gene set 
differentially expressed between GFP+ and GFP– gene ex-
pression profiles than has been previously reported. Those 
results are included in the present study, along with the 
pathways and ontologies enriched to the new gene set 
(see below). Genes differentially expressed greater than 
two-fold and posterior probability greater than 0.99 were 
used for the bioinformatics analysis. Enrichr [67], an open 
source and freely available gene list enrichment analysis 
tool, was used to identify enriched pathways for Kyoto 
Encyclopedia of Genes and Genomes (KEGG) [68], WikiP-
athways (WIKI) [69], BioCarta [70], protein–protein inter-
acting proteins (PPI Hub Proteins) [71], The Comprehen-
sive Resource of Mammalian Protein Complexes (CORUM) 
[72], Reactome [73] and Gene Ontology Process (GO) [74]. 
Each list of differentially expressed genes was uploaded to 
the Enrichr [67] website and pathways or ontologies en-
riched greater than a combined score (Score) of 5 were 
reported. The combined score is computed by taking the 
log of the p-value from the Fisher’s exact test multiplied 
by the Z-score of the deviation from the expected rank 
[67]. Among the differentially expressed genes, the most 
promising genes that may affect transfection were iden-
tified. The genes were selected based on high differential 
expression, putative gene role and potential to play a role 
in processes that are known to occur during DNA trans-
fer [3,19,30,31,39,41,45–52]. After identifying target genes, 
the NextBio [75] Pharmaco Atlas was used to identify 
pharmacologic agents known to upregulate or downreg-
ulate the target gene with a score above 70. Those phar-
macologic agents were then used for transfection stud-
ies in the presence of pharmacologic agents (see below). 
Transfection in the presence of pharmacologic agents 
These experiments were performed as previously de-
scribed to alter the expression of endogenous target genes 
identified from microarray analysis [42]. The studies acted 
primarily as a screening tool to confirm whether a par-
ticular gene plays an important role in the DNA transfer 
process. Briefly, transfection studies were performed in the 
presence and absence of pharmacologic activators or in-
hibitors of the target genes (selected as described above). 
HEK 293T cells were seeded in 48-well plates at 44.8×103 
cells/cm2 and, 18 h later, pharmacologic agents were de-
livered to the media on the cells to achieve the final de-
sired drug concentration. The pharmacologic agent was al-
lowed to incubate for 1 h, and then lipoplexes were formed 
(as described above) and delivered to the media above the 
cells (still containing the pharmacologic agent). The phar-
macologic agent and lipoplexes remained in contact with 
the cells for the next 24 h and then the cells were lysed and 
transfection levels were quantified by measuring the lucif-
erase activity (relative light units) using the Luciferase As-
say System (Promega, Madison, WI, USA) and luminometer 
(Turner Designs, Sunnyvale, CA, USA), and luciferase activ-
ity was normalized to the total protein amount determined 
with the BCA protein assay (Pierce, Rockford, IL, USA) and 
compared with transfection levels in vehicle-only control 
cells. The results were reported as the fold-change to elim-
inate variability in absolute measures of transfection, re-
spectively, for RGS1, ARHGAP24, PDZD2, SNX24, GSN and 
IGF2BP1 genes; pharmacologic activators included immu-
noglobin G [76], 5-episisomicin [77], apramycin [77], 4-hy-
droxytamoxifen [78], folic acid [79] and tetrachloroethylene 
[80]; and pharmacologic inhibitors included eicosapentae-
noic acid [81], cytoclasin B [82], tolazoline [77], benzoic 
acid [77], hydrocortisone [83] and propanil [84] (all from 
Sigma-Aldrich, St Louis, MO, USA); the concentrations of 
pharmacologic agents selected for the present study were 
comparative to those tested in the literature showing gene 
activity [77,82–84] but were optimized for high transfec-
tion and minimal toxicity (not shown) (see Supporting in-
formation, Figure S1). Statistical analysis was performed 
using Prism, version 5 (GraphPad, La Jolla, CA, USA) us-
ing Student’s t-test at a 95% confidence level. Data are re-
ported as the mean ±SEM (n=3). 
Results 
PEI polyplexes, carrying a plasmid encoding a GFP re-
porter gene, were delivered to HEK 293T cells. Then, 2 h 
after delivery of the polyplexes, we identified genes and 
pathways regulated in the initial response to treatment 
with polyplexes by comparing changes in the transcrip-
tome between cells treated by polyplexes with cells not 
treated by polyplexes (Figure 1). All genes found to be 
differentially expressed two-fold or greater are listed in 
the Supporting information (Table S1). Among the great-
est differentially expressed genes in cells treated com-
pared to untreated (at the 2-h time point) were: RGS1, AR-
HGAP24, PDZD2, SNX24, GSN and IGF2BP1, which were 
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downregulated by 6.9-, 11.8-, 38.3-, 45.4- and 48.8-fold, 
respectively (Table 1). Of all genes differentially expressed 
between treated and untreated cells at the 2-h time point 
(see Supporting information, Table S1), only YWHAE, EGR1 
and GSN were found to be enriched to cellular pathways, 
including kinase maturation, emerin, EGR-EP300 and pru-
negelsolin (Table 2). Taken together, treated cells were 
shown to undergo rapid transcriptional changes in re-
sponse to treatment with polyplexes in a highly down-
regulated manner. 
Because most cells internalize polyplexes within the 
first few hours of exposure [3,30,41,45,50–52; unpublished 
results, S.A.P] but not all cells eventually express the trans-
gene, we next set out to identify those endogenous genes 
that may facilitate transfection. To do so, polyplexes were 
delivered to the cells and, after 8, 16 or 24 h, the treated 
cell population was sorted into GFP+ and GFP– subpop-
ulations (Figure 1). Using microarray analysis, changes in 
the transcriptome were identified by comparing endog-
enous gene expression profiles between the GFP+ and 
GFP– subpopulations. All genes found to be differen-
tially expressed two-fold or greater are listed in the Sup-
porting information (Table S1). At the 8-h time point, the 
greatest differentially expressed genes between the GFP+ 
and GFP– populations were RAP1A, ACRC and ACTA1, up-
regulated by 22.71-, 7.75- or 6.01-fold, respectively (Ta-
ble 3). At the 16-h time point, the greatest differentially 
expressed genes were RAP1A, CHORDC1, NEB, WDR78, 
ACTA1, ACRC and PGAP1, upregulated by 13.20-, 9.36-, 
7.32-, 6.29-, 5.48-, 5.42- or 5.26-fold, respectively (Table 
3). At the 24-h time point, the greatest differentially ex-
pressed genes were RAP1A, SCG5, ACRC, ATF3, IREB2 and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACTA1, upregulated by 14.59-, 6.15-, 6.14-, 5.83-, 5.71- or 
5.04-fold, respectively (Table 3). 
We were next interested in understanding how the 
gene expression profile changes over time, in terms of 
number of genes expressed, as well as which genes were 
found to be differentially expressed over multiple time 
points. The number of genes differentially expressed (be-
tween GFP+ and GFP– cell populations) decreased from 
8 h to 16 h from 179 genes to 156 genes, respectively, 
with 14 genes commonly expressed between the two time 
points (see Supporting information, Table S2). The num-
ber of genes differentially expressed increased from 16 h 
to 24 h from 156 genes to 457 genes (Figure 2), respec-
tively, with 33 genes commonly being expressed between 
the two time points (see Supporting information, Table 
S2), and with IREB2 notably overexpressed five-fold. The 
largest number of genes differentially expressed occurred 
after 24 h of exposure to polyplexes (n=457) (Figure 2; 
Table 1. Cell shutdown in response to treatment with polyplexes
Gene  Fold Δ  Name
RGS1  –6.9  Regulator of G-protein signaling 1
ARHGAP24  –11.8  Rho GTPase activating protein 24
PDZD2  –14.9  PDZ domain containing 2
MARK1  –35.5  MAP/microtubule affinity-regulating kinase 1: accession AL049302
DENND4A  –37.1  DENN/MADD domain containing 4A: accession T86874
SNX24  –38.3  Sorting nexin 24
ZNF79  –40.2  Zinc finger protein 79
VNN3  –41.7  Vanin 3
C6orf148  –44.2  Chromosome 6 open reading frame 148: accession T97641
GSN  –45.4  Gelsolin
IGF2BP1  –48.8  Insulin-like growth factor 2 mRNA binding protein 1
CPB2  –49.8  Carboxypeptidase B2 (plasma)
IGLV3–25  –54.6  Immunoglobulin lambda variable 3–25
LGSN  –57.0  Lengsin, lens protein with glutamine synthetase domain
LOC400084  –57.6  Uncharacterized LOC400084
EXOC3L4  –58.3  Exocyst complex component 3-like 4
KRT27  –69.7  Keratin 27
Fold change indicates differential expression by comparing microarrays of HEK 293T cells treated with pEGFPLuc/LF2000 (n=3) with microarrays from 
untreated cells (n=3) with a posterior probability greater than 0.99 at the 2-h time point. Negative numbers indicate downregulation.
Table 2. Enriched pathways involved in the cell shutdown response
Source  Term  Score  Genes
CORUM  Kinase maturation complex 1  6.62  YWHAE
CORUM  Emerin complex 25 (human)  4.55  YWHAE
CORUM  EGR-EP300 complex (human)  4.44  EGR1
CORUM  Prune-Gelsolin complex (human)  4.39  GSN
Genes found in Table 1 were found to be over-represented to specific 
terms. The first column indicates the source of pathway database; 
the second column lists the enriched term, the third column lists the 
enrichment score; and the last column indicates which of the differentially 
expressed genes belong to the enriched term. Downregulated genes 
are shown in italic, upregulated genes are underlined, and genes 
greater than five-fold differentially expressed are shown in bold. For a 
description of the source or score, see Materials and methods.
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see also Supporting information, Table S2). Additionally, 
RAP1A, ERVK3-2, WDR78, ACRC, NEB, ACTA1, CHORDC1, 
SCG5, PGAP1, ATF3, AI939588 and AL833615 may play a 
role in multiple aspects that facilitate DNA transfer be-
cause they were overexpressed at each time point (Fig-
ure 2; see also Supporting information, Tables S1 and S2). 
To determine the role of all differentially expressed 
genes at each time point (8, 16 and 24 h; see Supporting 
information, Table S1), we performed a pathway and on-
tology enrichment analysis (Table 4; see Materials and 
methods). Pathways enriched from genes differentially 
expressed at the 8-h time point were muscle contraction, 
cell cycle process, cellular pathways (MPR, G2 and integ-
rin) and protein complexes (HDAC1, RC and ING2) (Table 
4). Pathways enriched at the 16-h time point were muscle 
contraction and the integrin pathway (Table 4). Pathways 
Table 3. Temporal cell response after treatment with polyplexes comparing GFP+ with GFP– gene expression profiles
   Posterior Accession 
Time  Gene  Fold Δ probability number  Name
8 h  *RAP1A  22.71  1.000  AB051846  RAP1A, member of RAS oncogene family
 ERVK3-2  8.97  1.000  NM–022155  Endogenous retrovirus group K3, member 2
 WDR78  7.90  1.000  BC032406  WD repeat domain 78
 *ACRC  7.75  1.000  AI091533  Acidic repeat containing
 NEB  6.45  1.000  NM–004543  Nebulin
 *ACTA1  6.01  1.000  NM–001100  Actin, alpha 1, skeletal muscle
 TPH1  5.54  1.000  AI350339  Tryptophan hydroxylase 1
 KIAA1731  5.33  1.000  AL833615  Centrosomal protein KIAA1731
 CKS2  –6.16  0.992  NM–001827  CDC28 protein kinase regulatory subunit 2
16 h  *RAP1A  13.20  1.000  AB051846  RAP1A, member of RAS oncogene family
 CHORDC1  9.36  1.000  AI473843  Cysteine and histidine-rich domain (CHORD) containing 1
 ERVK3-2  7.51  1.000  NM–022155  Endogenous retrovirus group K3, member 2 [NM–022155]
 NEB  7.32  1.000  NM–004543  Nebulin
 WDR78  6.29  1.000  BC032406  WD repeat domain 78
 *ACTA1  5.48  1.000  NM–001100  Actin, alpha 1, skeletal muscle
 *ACRC  5.42  1.000  AI091533  Acidic repeat containing
 PGAP1  5.26  1.000  BF063546  Post-GPI attachment to proteins 1
 KIAA1731  5.24  1.000  AL833615  Centrosomal protein KIAA1731
24 h  *RAP1A  14.59  1.000  AB051846  RAP1A, member of RAS oncogene family
 CHORDC1  10.95  1.000  AI473843  Cysteine and histidine-rich domain (CHORD) containing 1
 WDR78  8.78  1.000  BC032406  WD repeat domain 78
 PGAP1  7.70  1.000  BF063546  Post-GPI attachment to proteins 1
 ERVK3-2  6.65  1.000  NM–022155  Endogenous retrovirus group K3, member 2 [NM–022155]
 NEB  6.59  1.000  NM–004543  Nebulin
 *SCG5  6.15  1.000  NM–003020  Secretogranin V (7B2 protein)
 *ACRC  6.14  1.000  AI091533  Acidic repeat containing
 *ATF3  5.83  1.000  NM–001674  Activating transcription factor 3
 *IREB2  5.71  1.000  BC017880  Iron-responsive element binding protein 2
 AI939588  5.10  1.000  AI939588  NA
 *ACTA1  5.04  1.000  NM–001100  Actin, alpha 1, skeletal muscle
 AW627671  –5.16  0.996  AW627671  NA
 AL530869  –5.34  0.997  AL530869  NA
 NDUFA13  –5.58  0.994  NM–015965  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13
 KIAA1324  –5.66  0.993  AB037745  KIAA1324
 RBBP4  –5.71  0.991  BC003092  Retinoblastoma binding protein 4
 FAF2  –5.72  0.990  AB020694  Fas associated factor family member 2
 HEATR1  –5.78  0.992  NM–018072  HEAT repeat containing 1
 AGBL3  –6.22  0.996  NM–024856  ATP/GTP binding protein-like 3
 MAPK1IP1L  –6.51  0.996  AI671747  Mitogen-activated protein kinase 1 interacting protein 1-like
 DNAJA1  –6.85  0.996  NM–001539  DnaJ (Hsp40) homolog, subfamily A, member 1
 SNHG6  –7.63  0.997  BG169443  Small nucleolar RNA host gene 6 (nonprotein coding)
 EIF4A2  –8.60  0.996  NM–001967  Eukaryotic translation initiation factor 4A2
 TRA2B  –9.44  0.998  NM–004593  Transformer 2 beta homolog (Drosophila)
 CKB  –9.84  0.991  NM–001823  Creatine kinase, brain
 ACTB  –15.16  0.995  NM–001101  Actin, beta
 ND2  –17.83  0.998  NM–173709  MTND2
 AF253979  –18.74  0.997  AF253979  NA
Comparison of GFP+ with GFP– gene expression levels. Differential expression greater than or less than 1 represents upregulation or downregulation, 
respectively. Data represent genes differentially expressed comparing transfected microarrays (n=3) with treated, untransfected microarrays (n=3) 
with a posterior probability greater than 0.99 and differential expression greater than five-fold. The Supporting information (Table S1) lists all genes 
differentially expressed greater than two-fold. Genes indicated with an asterisk (*) represent genes previously identified to alter transfection [43]. 
NA: not available.
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enriched at the 24-h time point nucleic acid binding, reg-
ulation of transcription, RNA metabolism and processing, 
response to DNA damage, nuclear factor-kappa B (NF-κB) 
protein hub and the androgen receptor signaling pathway 
(Table 4). Because the transfected cells (GFP+) exhibited 
different genes and enriched pathways at each time point 
compared to untransfected cells (GFP–), those genes and 
pathways may play a role in transfection. 
As reported in the present study, microarray analysis re-
vealed genes highly differentially expressed in treated cells 
compared to untreated cells at the 2-h time point and in 
GFP+ cells compared to GFP– cells at the 8-, 16- and 24-h 
time points (Tables 1 and 3). To discriminate whether any 
of the genes identified in the present study have a po-
tential role in transfection as opposed to genes that are a 
treatment effect, pharmacologic studies were conducted. 
Those genes highly differentially expressed at 2-, 8-, 16- 
or 24-h time points (Tables 1 and 3) were narrowed to 
a smaller subset to further test based on a literature re-
view of each gene’s putative function and potential role in 
the DNA transfer process. Highly differentially expressed 
genes RAP1A, ACRC, ACTA1, SCG5, ATF3 and IREB2 (Ta-
ble 3) were not studied here using pharmacologic agents 
because we have previously shown that perturbing those 
genes prior to polyplex delivery can enhance transfection 
by up 2.5-fold [43], suggesting a role for those genes in 
transfection. The list of genes was narrowed to RGS1, AR-
HGAP24, PDZD2, SNX24, GSN and IGF2BP1. Pharmaco-
logic agents known to activate or inhibit each gene were 
determined using NextBio [75] and from previous studies 
in the literature [77,82,85–87] and used as a screening tool 
to confirm whether a particular gene may play an impor-
tant role in the DNA transfer process. The effects of the 
pharmacologic agent on transfection levels are summa-
rized in Table 5 with transfection levels provided in Figure 
3. In all pharmacologic studies reported here, little-to-no 
cytotoxicity was observed (see Supporting information, 
Figure S1) at the concentrations used. 
For every target gene investigated, opposing phar-
macologic treatments resulted in opposing transfection 
trends (i.e. if activating a target gene resulted in enhanced 
transfection, then inhibiting that same target gene re-
sulted in decreased transfection) (Figure 3 and Table 5). 
There was no trend of whether activation of the target 
gene always lead to increased transfection or whether in-
hibition of the target gene lead to decreased transfection 
(Figure 3 and Table 5). Targets and treatments that re-
sulted in increased transfection relative to untreated con-
trols were: RGS1 inhibited by 3 μM eicosapentaenoic acid 
[81] (1.2- fold), ARHGAP24 inhibited by 1 μM cytoclasin 
B [82] (1.7-fold), SNX24 activated by 10 μM 4-hydroxy-
tamoxifen [78] (5.3-fold), GSN inhibited by 10 μM hydro-
cortisone [83] (2.5-fold) and IGF2BP1 activated by 1 nM 
tetrachloroethylene [80] (1.2-fold) (Figure 3 and Table 5). 
Targets and treatments that resulted in decreased trans-
fection relative to untreated controls were: RGS1 activated 
by 0.1 μM immunoglobin G [76] (5.7-fold), ARHGAP24 ac-
tivated by 0.1 μM 5-episisomicin [77] (5.2-fold), PDZD2 in-
hibited by 0.1 μM tolazoline [77] (4.4-fold), SNX24 inhib-
ited by 1 μM benzoic acid [77] (4.0-fold), GSN activated by 
1 μM folic acid [79] (5.2-fold) and IGF2BP1 inhibited by 1 
μM propanil [84] (4.8-fold) (Figure 3 and Table 5). When 
PDZD2 was activated by 30 μM apramycin [77] prior to 
delivery of polyplexes, transfection was unchanged. Taken 
together, altering RGS1, ARHGAP24, PDZD2, SNX24, GSN 
and IGF2BP1 gene activity can affect transfection, show-
ing that microarray analysis can identify genes possibly 
playing a role in transfection. 
We next set out to identify a molecular component 
to explain the mechanistic differences of transfection ob-
served for polyplexes and lipoplexes [14,29–34,44,58–64]. 
The number and type of differentially expressed genes 
for each DNA carrier over time was examined. Relative to 
control, 2 h after treatment of cells with polyplexes (pres-
ent study) or lipoplexes [53], a similar number of genes 
were downregulated in response to treatment with com-
plexes (46 genes for polyplexes; 44 genes for lipoplexes) 
Figure 2. The overlap of genes differentially expressed between the 
GFP+ and GFP– gene expression profiles is shown for each time point. 
Numbers in white encircled by a black background represent the total 
number of genes greater than two-fold differentially expressed com-
paring transfected microarrays (GFP+; n=3) with treated, untransfected 
microarrays (GFP–; n=3) with a posterior probability greater than 0.99. 
Genes that are greater than five-fold differentially expressed are listed 
by name. The specific genes associated with the Venn diagram are listed 
in the Supporting information (Table S2). The level of differential expres-
sion for each gene is provided in the Supporting information (Table S1). 
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(Figure 4) but no gene was commonly involved in the 
transcriptional shutdown of each vector. Comparing GFP+ 
cells with GFP– cells, 8 h after exposure of complexes to 
cells, 179 genes were differentially expressed for poly-
plexes and only seven genes for lipoplexes (Figure 4), 
with RAP1A and ATF3 commonly being differentially ex-
pressed for both DNA carrier systems. Comparing GFP+ 
cells with GFP– cells, 16 h after exposure of complexes to 
cells, 156 genes were differentially expressed for poly-
plexes and only 27 genes for lipoplexes (Figure 4), with 
ZNF236, RAP1A, ZRSR1, ZNF79 and ATF3 commonly dif-
ferentially expressed for both DNA carrier systems. Com-
paring GFP+ cells with GFP– cells, 24 h after exposure 
of complexes to cells, 456 genes were differentially ex-
pressed for polyplexes and only two for lipoplexes (Figure 
4), with RAP1A and HSPA6 commonly being differentially 
expressed for both DNA carrier systems. Taken together, 
cells immediately respond to treatment with complexes 
via a downregulation of transcription with either lipid or 
polymer gene carriers. At later time points, GFP+ cells 
Figure 3. Effect of target gene on transfection for HEK 293T cells treated with indicated pharmacologic agent (black bars) or treated only with vehicle 
used to deliver the pharmacologic agent (Control+; open bars) (Table 5) to activate (underlined text) or inhibit (plain text) indicated genes. After a 1-h 
incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h (see Materials and methods). Data are reported as the 
mean±SEM (n=3) and significant changes between treated and vehicle-only transfection levels are indicated as: * p < 0.05 ; ** p < 0.01 ; or *** p < 0.001. 
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exhibit a different gene profile relative to GFP– cells after 
exposure to complexes, although polyplexes overexpress 
a much greater number of genes compared to lipoplexes. 
Finally, when comparing GFP+ cells with GFP– cells, the 
level of differential expression of genes from microarrays 
found in the present study for polyplexes (RAP1A, SCG5, 
IREB2, PGAP1 and ACTA1; Table 4) was compared with the 
level of differential expression of genes found for lipo-
plexes (RAP1A, HSPA6 and PACSIN3) in our complemen-
tary study [53] at 2, 8, 16 and 24 h after delivery of com-
plexes to the cells (Figure 5). The differential expression 
trend and values for RAP1A, HSPA6 and ATF3 appeared to 
be similar in both lipoplex- and polyplex-mediated trans-
fection at each time point (2, 8, 16 and 24 h) after delivery 
of either type of complex, except for the 2-h time point 
for RAP1A, where it was downregulated by 12.5-fold in 
polyplexes but upregulated by 7.5-fold in lipoplexes (Fig-
ure 5). For PACSIN3, the differential expression trend and 
values after treatment of cells by lipoplexes or polyplexes 
was generally that of downregulation (Figure 5), although 
a 6.6-fold upregulation of PACSIN3 was observed at the 
8-h time point for lipoplexes. At the 2-h time point, SCG5, 
IREB2, PGAP1 and ACTA1 were downregulated for both 
polyplexes and lipoplexes. For lipoplexes, these genes 
Figure 4. Overlap of the number of differentially expressed genes when comparing those genes identified in polyplex transfection (present study) 
with lipoplex transfection [53]. The number of genes differentially expressed are shown for each time point (2 h comparing treated with untreated 
gene expression profiles; 8, 16 and 24 h comparing GFP+ with GFP– gene expression profiles) and DNA carrier (PEI, LF2000). Data represent genes 
greater than two-fold differentially expressed comparing treated and untreated microarrays (n=3) or GFP+ and GFP– microarrays (n=3) with a pos-
terior probability greater than 0.99. The specific genes associated with the Venn diagram are listed in the Supporting information (Table S3). The 
level of differential expression for each gene is provided in the Supporting information (Table S1) for polyplexes or as supplemental information in 
our other work for lipoplexes [53].  
Figure 5. DNA carrier dependency on expression of differentially expressed genes for PEI (dashed line with diamonds) and LF2000 (solid line with 
squares). Data represent the values obtained from microarray analysis [66] (see Methods and Materials) comparing transfected cell arrays (GFP+; 
n=3) with treated, untransfected cell arrays (GFP–; n=3). Filled markers represent posterior probability values ≥ 0.9, whereas unfilled markers rep-
resent a posterior probability <0.9. The level of differential expression for each gene is provided in the Supporting information (Table S1) for poly-
plexes or in our other work for lipoplexes [53].  
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were then upregulated at the 8-, 16- and 24-h time points 
but remained downregulated for polyplexes over the same 
time period (Figure 5). Taken together, relative to GFP cells, 
GFP+ cells act to overcome the cellular downregulation of 
transcription observed 2 h after delivery of lipoplexes or 
polyplexes using some of the same genes (RAP1A, HSPA6 
and ATF3) (Figure 5), whereas polyplexes exhibit a much 
larger and sustained expression of genes over time (Figure 
4), with a polyplex-specific response to upregulate SCG5, 
IREB2, PGAP1 and ACTA1 genes (Figure 5). 
Discussion 
Understanding the intracellular molecules and pathways 
that may facilitate DNA transfer provides insight into the 
potential mechanisms required for efficient transfection 
[88], offering targets for designing enhanced nonviral 
gene delivery systems. Gene transfer requires molecu-
lar mediators to actively transfer the delivered DNA [41] 
through intracellular barriers, into the nucleus [20–28,45] 
and for transgene expression [89]. Although the routing 
kinetics of the polyplexes have been observed as they 
occur over time and enable the development of trans-
fection models [30–33,64], the molecular mediators used 
by the cell to route the DNA complex are poorly under-
stood. In the present study, we attempted to fill that gap 
in knowledge using a transcriptomics approach aimed at 
identifying molecules and pathways involved in key cel-
lular events known to influence transfection at 2, 8, 16 
and 24 h after polyplex delivery. Because mRNA metab-
olism and catabolism can be condition- and cell-specific 
and mRNA half-life widely varies from approximately 10 
min to 10 h or more, our approach may miss the iden-
tification of molecules involved in short-lived signaling 
pathways. To address this challenge of using microarrays 
and a few selected time points, we integrated the identi-
fied endogenous genes and pathways from the present 
study with other studies that identified short-lived sig-
naling events into a proposed preliminary model of the 
biology of transfection of HEK 293T cells by polyplexes 
(Figure 6). The endogenous genes and pathways are dis-
cussed below in the context of the cellular processes and 
timing of those processes that occur during DNA trans-
fer. Additionally, we compared and contrasted molecu-
lar mechanisms of transfection used by polyplexes and 
lipoplexes since both vectors show promising in vitro 
and in vivo transfection [40], although no molecular dif-
ferences have been identified to account for the mech-
anistic differences in transfection from the two vectors 
[14,29–34,44,58–64]. 
Treatment of cells with polyplexes results in a 
cellular downregulation of transcription 
In the present study, gene expression profiles were ob-
tained for HEK 293T cells treated with polyplexes for 2 
h compared to untreated cells (Figure 1). Relative to un-
treated cells, our results show that HEK 293T cells treated 
with polyplexes exhibited a marked downregulation of 46 
genes (Figure 4; see also Supporting information, Table 
S1). During this period, polyplexes have been shown to in-
ternalize into and escape from the endosomes [13,30,31] 
at the same time as the cell is actively coping with the cy-
totoxic stress induced by polyplexes [13] or foreign DNA 
[90] (Figure 6). Various strategies have been devised to 
reduce the cytotoxicity by altering delivery techniques, 
such as complex maturation time, polymer amine to DNA 
phosphate charge ratio (N:P) or size of polyplexes [90,91], 
and formulations, such as molecular weight [13], polymer 
blending (e.g. PEI) [92] or including lipid coatings such 
as with lysinylated and histidylated cholesterol [93]. An-
other group used microarrays to identify molecules in-
volved in endosomal escape of a PEGylated polyplex for-
mulation to guide improvements of a new delivery system, 
which included a GALA fusogenic peptide [59]. That study 
[59], as well as our previous microarray studies [42,43], 
demonstrates that the identification of the molecules in-
volved in transfection can be used for targeted improve-
ments to gene delivery systems. Because all of the genes 
identified in the present study at the 2-h time point were 
highly downregulated, the cellular response to exposure 
of polyplexes is suggestive of a type of cellular shutdown 
of transcription, presumably to prevent further cytotoxic 
assault [13] and further uptake of the foreign DNA [90]. 
We also noted that total RNA was reduced in samples 
treated with polyplexes compared to untreated samples 
(data not shown). The transcriptional shutdown in re-
sponse to short-term stress is reported to occur in other 
eukaryotic systems that act to rapidly destabilize mRNAs 
and coordinate mRNA turnover within a few minutes to 
achieve strong activity of stress genes [94]. In the pres-
ent study, we identified RGS1, ARHGAP24, PDZD2, SNX24, 
GSN and IGF2BP1 genes (Table 1) to be downregulated 
after a 2-h exposure to polyplexes; those genes are dis-
cussed below in terms of potential hallmarks of the cell 
shutdown. However, whether the shutdown is a positive or 
negative event for transfection is unclear because some-
times activating the target gene improved transfection, 
at the same time as inhibiting a different target gene also 
improved transfection (Figure 3 and Table 5). The results 
from our studies demonstrate that there are many genes 
responsible for DNA transfer at different time points and 
that activating or inhibiting a single gene is unlikely to 
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have a prodigious effect on DNA transfer, agreeing with 
our pharmacologic studies. 
One mechanism that may participate in the cell shut-
down event is the interactions of filopodia with poly-
plexes. Filopodia are slender, actin-rich protrusions that 
extend outward from the cell body to sense the extracel-
lular environment. Filopodia have recently been reported 
to bind and process complexes prior to cellular entry via 
endocytosis [58,95]. Three genes identified in the pres-
ent study (ARHGAP24, GSN and IGF2BP1) are implicated 
in the generation of such podia protrusions, which the 
cell may downregulate to avoid further endocytosis of 
foreign DNA via cilia (Figure 6). ARHGAP24, when over-
expressed, disrupts actin stress fibers and the formation 
of filopodia [96] and, when activated (5-episisomicin, an 
aminoglycoside antibiotic) in the present study, transfec-
tion was decreased by 5.2-fold (Table 5). Similarly, inhib-
iting the disruption mechanism using cytoclasin B (inhib-
its actin filament polymerization) resulted in a 1.7-fold 
increase in transfection. GSN also promotes ciliogenesis 
and inhibits apoptosis in stressed cells by means of a sta-
bilizing actin mesh [97]. Activating GSN by use of folic acid 
(B vitamin needed for DNA synthesis, repair or methyla-
tion) resulted in a 5.2-fold decrease in transfection, even 
though endocytosis was probably enhanced as a result of 
promoting the production of filopodia. The loss in trans-
fection levels was probably a result of the polymerized 
actin mesh acting to impede nuclear localization of the 
pDNA [98]. Inhibiting GSN by hydrocortisone (steroid hor-
mone that improves metabolism and suppresses immune 
response) resulted in a 2.5-fold increase in transfection 
(Table 5), presumably by enhancing nuclear localization 
of pDNA as reported previously [99]. Finally, cells with 
IGF2BP1 downregulated have been previously reported to 
exhibit reduced focal complexes [100], reduced filopodia 
[100] and reduced proliferation [101], processes shown to 
affect transfection. Hence, inhibiting IGF2BP1 by propa-
nil (herbicide with immunomodulatory activity in eukary-
otes) resulted in a 4.8-fold decrease in transfection, at the 
same time as activating IGF2BP1 (tetrachloroethylene, a 
Figure 6. Proposed interaction of genes and pathways during pDNA transfer as identified in the present study. Shown is the outline of a HEK 293T 
cell with a partial outline of a daughter cell shown in the upper right. The DNA transfer process is shown within the cell, with the initial event of the 
complex binding to the cell occurring at the far left at time 0 h and subsequent events (large red arrows) occurring over time, from left-to-right. The 
time points chosen for microarray analysis in the present study are indicated with a green arrow at the bottom and correspond with molecular events 
shown above the arrow within the cell. Genes, enriched pathways and molecular intermediates as identified or discussed in the present study at each 
time point appear in the context of the DNA transfer process. Multiple molecular intermediates remain unlisted. PEA, phosphorylethanolamine; GPI-
AP, glycosylphosphatidylinositol-anchored proteins; MPR, mannose 6-phosphate receptor.   
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lysosomal membrane disruptor) resulted in a 1.2-fold in-
crease in transfection (Table 5). Taken together, we confirm 
the role of ARHGAP24, GSN and IGF2BP1 genes on trans-
fection and also that those genes may be contributing to 
low transfection efficiency, potentially by altering cellular 
processes affecting transfection in cytoskeletal signaling 
[102], filopodia [58,103,104] and the ability to cope with 
cellular stress [42,43,100] (Figure 6). 
A second mechanism that may participate in cell shut-
down is GTPase signaling. ARHGAP24, GSN and IGF2BP1 
genes (discussed above in the context of filopodia) and 
RGS1 are all GTPases that were downregulated at the 2 h 
time point in treated cells compared to untreated (Figure 
6). RGS1 is as a GTPase activating protein (GAP), which 
rapidly acts to turn off G-protein-coupled receptor sig-
naling and may play an inflammatory and immunological 
role after bacterial and viral infection [105]. RGS1 report-
edly exhibits an immediate upregulation after bacterial or 
viral infection and is subsequently downregulated after 30 
min [105]. The altered expression of RGS1 observed in the 
present study after polyplex exposure to HEK 293T cells 
(Table 1) may act to disrupt GTPase signaling and prevent 
further uptake of the foreign DNA (Figure 6). Therefore, 
we hypothesized that activating or inhibiting RGS1 prior 
to delivery of polyplexes would lead to decreased or en-
hanced transfection, respectively. In support of our hy-
potheses, activating (immunoglobin G, an antibody iso-
type) or inhibiting (eicosapentaenoic acid, involved in 
immune and inflammatory responses) RGS1 resulted in 
a 5.7-fold decrease or a 1.2-fold increase in transfection, 
respectively (Table 5). One potential explanation of the al-
tered transfection is that a similar mechanism may be at 
play as in a recent study showing that activation of regu-
lators of G-protein signaling (RGSs) prevent cyclic adenos-
ine monophosphate and protein kinase A activity [106], 
and protein kinase A has been recently shown to modu-
late intracellular routing of polyplexes [107]. Another po-
tential mechanism of altered transfection is that RGS1 is 
a GAP that would alter cellular cytoskeleton dynamics via 
RhoGTPase signal transduction and therefore alter inter-
nalization and intracellular processing of polyplexes [108]. 
In either event, altering the expression level of RGS1 can 
alter nonviral transfection possibly via G-coupled signal 
transduction (GTPases Rho, Rac and CDC42) [108] ending 
in processes known to affect transfection, such as endo-
cytosis [109], cell spreading, migration, stress fibers, focal 
adhesion [102] and cell motility (Figure 6). 
One last mechanism that may also participate in the 
cell shutdown is endosomal uptake, a critical process in-
volved in transfection [109–111]. In the present study, two 
genes that play a role in endocytosis, PDZD2 and SNX24, 
were highly differentially expressed in HEK 293T cells after 
2 h of exposure to polyplexes (Table 1). The protein en-
coded by PDZD2 contains the PDZ (postsynaptic density 
95/discs large/zonus occludens-1) domain that interacts 
with syndecans and proteoglycans that facilitate zippering 
of vesicles around polyplexes for endocytosis [112]. Hence, 
PDZD2 may be involved in endocytosis of polyplexes be-
cause inhibiting the gene (by tolazoline, an adrenergic 
α-antagonist) resulted in a 4.4-fold decrease in transfec-
tion. In addition, the sorting nexin (SNX) family of proteins 
is involved in various aspects of endocytosis [113]. SNX24, 
identified as differentially expressed, may be involved in 
endocytic uptake of polyplexes because, in activating (by 
4-hydroxytamoxifen, binds to estrogen receptor and al-
ters expression of estrogen-dependent genes) or inhibit-
ing (by benzoic acid, which alters glycine-dependent me-
tabolism) SNX24, we saw a 5.3-fold increase or 4.0-fold 
decrease in transfection, respectively (Table 5). Taken to-
gether, given the downregulation of so many genes at the 
2-h time point, the cell may act to shutdown certain pro-
cesses to prevent further uptake of polyplexes such as fi-
lopodia [18,50] (ARHGAP24, GSN, IGF2BP1, and PDZD2), 
GTPases [108] (ARHGAP24, GSN, IGF2BP1, RGS1) and en-
docytic uptake or escape [109–111] (PDZD2 and SNX24) 
(Figure 6). Such a shutdown has been reported after viral 
infection, where host-cell transcription and nucleocyto-
plasmic trafficking is halted [114], although the event has 
not been reported for nonviral transfection. Nonetheless, 
by modulating the expression of genes identified in the 
present study, we were able to alter transfection, although 
how the concerted cellular shutdown of transcription af-
fects transfection remains unclear. 
Transfected cells overcome cell shutdown and 
barriers to transfection 
As described above, 2 h after polyplex delivery, all cells 
exhibited a ‘shutdown’, as indicated by the highly down-
regulated nature of all differentially expressed genes (see 
Supporting information, Table S1) and reduction of to-
tal RNA (data not shown). However, although not all cells 
will go on to express the transgene, some cells (GFP+) 
do overcome the shutdown event and express the trans-
gene. Several cellular processes are known to occur over 
the course of the next hours (until transgene expression 
is detected) (Figure 6), as shown in trafficking studies in 
the literature [3,19,30,31,39,41,45–49]. What remains un-
known are the molecules and pathways that participate 
in those processes. By comparing gene expression pro-
files for transfected cells (GFP+) with untransfected cells 
(GFP–) over a time course of transfection, we were able to 
identify potential genes that may aid in overcoming bar-
riers to transfection.  
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Relative to GFP– cells, we found several genes to be 
upregulated after exposure of polyplexes to cells at the 
8-h time point (ACTA1, NEB and RAP1A, among others), 
16-h time point (ACTA1 and RAP1A) and 24-h time point 
(ATF3 and IREB2). ACTA1 encodes the protein that forms 
microfilaments, a major component of the cytoskeleton, 
and can affect cytoskeletal organization to enhance trans-
fection [43,115]. NEB encodes nebulin that has several do-
mains that may play essential roles in cell migration, mo-
tility, cytoskeletal dynamics and focal adhesions [116,117]. 
ATF3 encodes an immediate-early gene that acts as a re-
pressor of ATF promoter sites and is inducible through 
the NF-kB and JNK/SAPK signal transduction pathway 
[46,118,119], such as by cell stress from nondegradable, 
free PEI [120] or the presence of foreign DNA [121,122]. 
IREB2 (iron-responsive element binding protein 2) is acti-
vated in response to oxidative stress and energy metabo-
lism [123,124], such as increased tricarboxylic acid (cycle 
activity required during the cell cycle [123,125]. The dif-
ferentially expressed genes identified in the present study 
(ACTA1, NEB, RAP1A, ATF3 and IREB2) are known to affect 
processes that would affect transfection such as endocy-
tosis [126,127], cytoskeletal signaling [102], nuclear local-
ization [19,30,47], nuclear entry [3,30,39,47], GFP synthe-
sis [30,48] and the cell cycle [49,109,110] (Figure 6). In our 
previous work, inhibiting ACTA1 or activating RAP1A prior 
to delivery of polyplexes resulted in a 1.7-fold increase or 
2.0-fold decrease in transfection [43], respectively. Simi-
larly, in our previous work, inhibiting ATF3 or activating 
IREB2 prior to delivery of polyplexes resulted in a 2.3-fold 
decrease or a 2.2-fold increase in transfection [43], re-
spectively. Taken together, ACTA1, NEB, RAP1A, ATF3 and 
IREB2 genes may help to overcome the cell shutdown and 
barriers to transfection by upregulating mechanisms in-
volved in binding DNA and trafficking [30,31,39,47], reg-
ulating cell stress, regulating cell cycle [47,49] and regu-
lating protein folding [30,31,43,48] (Figure 6). 
Molecular and mechanistic differences  
between polyplex-mediated transfection  
and lipoplex-mediated transfection 
Apparently, lipid- and polymer-based gene delivery sys-
tems achieve the same goals in gene transfer in that the 
pDNA must be internalized and then translocated and 
imported into the nucleus. Yet, transfection efficiencies 
from LF2000 lipoplexes are typically better than PEI poly-
plexes, presumably as a result of the mechanistic differ-
ences in transfection, such as: (i) the size and charge of the 
nanoparticle formed, which influences the uptake path-
way and transfection [56,57]; (ii) the nondegradable na-
ture of PEI, which may lead to immediate and sustained 
cytosolic stress [3,13]; (iii) the endosomal escape mecha-
nism (i.e. PEI causes plasmids to escape the endosome as 
the endolysomal pressure builds, whereas LF2000 causes 
plasmids release to be slow and sustained) [58]; and (iv) 
the reported pharmacogenomics [14,29,34,44,59–63] and 
pharmacokinetic [30–33,64] differences. In the present 
study, by comparing gene expression profiles between 
LF2000- and PEI-mediated transfection, we attempted to 
identify potential molecular differences that may account 
for the observed mechanistic differences listed. 
No common genes were found to be differentially ex-
pressed 2 h after exposure to lipoplexes or polyplexes 
(Figure 4), yet a similar number of genes was downregu-
lated. It is increasingly recognized that the initial binding 
and uptake route of the lipoplex or polyplex largely affects 
its cellular fate, and hence, transfection capacity [56,110]. 
Genes potentially affecting uptake and found for poly-
plexes (in the present study; RGS1, ARHGAP24, PDZD2, 
SNX24, GSN and IGF2BP1) (Table 4) or lipoplexes (ALMS1, 
ITGB1, FCGR3A, DOCK10, PACSIN3 and ZDDHC13; in our 
complementary work) [53] have a similar function in in-
fluencing transfection by filopodia [18,50], GTPase signal-
ing [108] and endocytic uptake or escape [109–111]. De-
spite different genes being downregulated, the cellular 
response to both polyplexes and lipoplexes is one exhibit-
ing transcriptional shutdown. However, the different genes 
reported in the present study may account for the mech-
anistic differences observed in physiochemical properties 
(chemistry, size, charge) [128–130], uptake pathway (which 
is cell type-, size- and vector-dependent) [56,57,96,128–
132], endosomal escape [58] and transfection from lipo-
plexes and polyplexes. 
After the cellular shutdown of transcription as a result 
of treatment of cells with complexes (Table 1), only a por-
tion of the treated cells can overcome the shutdown and 
barriers to transfection (GFP+). We also identified poten-
tial genes and pathways involved in overcoming cell shut-
down and overcoming barriers to transfection 8, 16 or 24 
h after delivery of polyplexes (RAP1A, SCG5, IREB2, PGAP1, 
ATF3 and ACTA1 (Figures 4 and 5 and Table 4) or lipo-
plexes (RAP1A, HSPA6, ATF3 and PACSIN3; in our comple-
mentary work) [53] to cells. Similar expression level trends 
during DNA transfer were observed in the GFP+ cells for 
RAP1A, ATF3 and HSPA6 after both polyplex- and lipoplex-
mediated transfection (Figure 5), highlighting a common 
role for these genes in transfection. Because the expres-
sion levels were sustained over many hours, those genes 
may play a broad role in cellular processes that occur to 
overcome barriers to transfection such as escape [41,45], 
followed by unpacking of plasmid [45,46], nuclear local-
ization [19,30,31,41,45,47], nuclear entry [30,39,47] and 
GFP synthesis [30,48]. By contrast, relative to GFP– cells, 
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GFP+ cells overexpressed SCG5, IREB2, PGAP1 and ACTA1 
after polyplex-mediated transfection but not for lipoplex-
mediated transfection at the 8-, 16- and 24-h time points 
(Figure 5). Those genes may contribute to the mechanis-
tic differences in polyplex and lipoplex transfection such 
as cytosolic stress [3,13], intracellular accumulation within 
endolysosome compartments [111,133,134], transgene 
expression kinetics [30–33,64] and level [135]. As one ex-
ample, SCG5 and PGAP1 are overexpressed after polyplex-
mediated transfection (Figure 5) but, in our previous work, 
activating SCG5 prior to delivery of polyplexes leads to 
reduced transfection [43]. However, SCG5 and PGAP1 are 
not overexpressed throughout lipoplex-mediated trans-
fection (Figure 5), and may suggest a molecular mecha-
nism by which lipoplexes transfect better than polyplexes. 
Taken together, HEK 293T cells that overcome cell shut-
down and cellular barriers to transfection may use some 
similar mechanisms (RAP1A, ATF3, HSPA6) and distinct 
mechanisms (SCG5, PGAP1) in response to PEI polyplex 
transfection or LF2000 lipoplex transfection, respectively. 
The number of genes differentially expressed at any 
time point were always lower for LF2000 compared to PEI 
(Figure 4). LF2000-mediated transfection typically exhib-
its lower cytotoxicity compared to PEI-mediated transfec-
tion (unpublished results, T.M.M.) and may account for 
the differences in gene expression responses between 
the two vectors. Many of the genes elicited for PEI in the 
present study were indicative of cellular stress, with dif-
ferentially expressed genes identified in pathways such 
as DNA damage, cell cycle checkpoints, and regulators 
of metabolism and transcription (Table 4) (ATF3, IREB2, 
NDUFA13, DDIT3). By contrast, many of the genes elic-
ited for LF2000 were enriched in pathways involved in 
integrin signaling, spindle formation and focal adhesion 
(RAP1A and AURKA; in our complementary work) [53], al-
though evidence of cytotoxicity may exist because the re-
sponse to unfolded protein pathway was enriched involv-
ing HSPA6. The nondegradable nature of PEI may lead to 
immediate and sustained cytosolic stress [3,13], and ex-
plain why such a higher number of genes was differentially 
expressed over time. That stress may be contributing to 
the reduced transfection observed from polyplexes, rela-
tive to lipoplexes, and could represent a major target for 
improving transfection from new gene delivery systems. 
Conclusions 
Identifying those genes and pathways that aid in over-
coming barriers to transfection provide targets for en-
gineering enhanced delivery systems and enabling their 
therapeutic use. In the present study, we began such an 
endeavor using microarray analysis to provide a tempo-
ral and high throughput view of the genes and pathways 
that occur during DNA transfer when using polyplexes, 
and extended our endeavor to lipoplexes (in our comple-
mentary work) [53]. Treating cells with polyplexes or lipo-
plexes resulted in a cellular shutdown of transcription of 
distinct genes involved in similar processes, including fi-
lopodia (polyplexes: ARHGAP24, PDZD2, GSN, IGF2BP1; 
lipoplexes: ALMS1, FCGR3A, DOCK10), GTPase signaling 
(polyplexes: RGS1, ARHGAP24; lipoplexes: DOCK10, ZD-
DHC13) and membrane trafficking (polyplexes: SNX24; li-
poplexes: PACSIN3, ZDDHC13). The genes appear to be 
important to DNA delivery because of their ability to mod-
ulate transfection. Possibly more important, however, are 
the genes and pathways utilized by transfected cells to 
overcome barriers to transfection. We found RAP1A, ATF3 
and HSPA6 genes to facilitate polyplex- and lipoplex-me-
diated DNA delivery, although polyplex-mediated DNA 
delivery elicited a much greater transcriptomics response, 
with distinct genes potentially a result of higher toxicity. 
Genes such as ATF3, IREB2, NDUFA13 and DDIT3 were 
only differentially expressed between GFP+ and GFP– 
cells treated with polyplexes but not lipoplexes. Those 
genes were found, in the present study, to be involved 
in DNA damage, cell cycle checkpoints, and regulators of 
metabolism and transcription. The genes, pathways and 
pharmacologic agents identified to alter transfection for 
polyplexes (present study) and lipoplexes (in our com-
plementary work) [53] provide a basis to further explore 
mechanisms of DNA transfer, prime cells for enhanced 
transfection from existing DNA delivery strategies and en-
gineer novel nonviral systems that can achieve enhanced 
transgene expression.     
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Figure S1. Phase images taken on Leica DMI 3000B (Bannockburn, IL, USA) to assess cell viability and morphology. HEK 293 T cells were seeded, al-
lowed to adhere (approximately 18 h); then pharmacologic agent or vehicle control + was delivered to the media above the cells and after a 1-h in-
cubation, lipoplexes were formed and delivered to the cells. After 24 h, images were taken at ×100 magnification (scale bar is the same for all im-
ages and as shown is 200 μM), with representative images shown. (A) Immunoglobin G 0.1 μM, (B) eicosapentaenoic acid 3 μM, (C) 5-episisomicin 
0.1 μM, (D) cytoclasin B 1 μM, (E) apramycin 30 μM, (F) tolazoline 0.1 μM, (G) 4-hydroxytamoxifen 10 μM, (H) benzoic acid 1 μM, (I) folic acid 1 μM, 
(J) hydrocortisone 10 μM, (K) tetrachlorethylene 1 nM, (L) propanil 1 μM, (M) 0.1M NaCl vehicle control+, (N) MeOH vehicle control+, (O) ddH2O ve-
hicle control+, (P) DMSO vehicle control+, (Q) 1M NaOH vehicle control+ and (R) control–.  
Table S1. Genes differentially expressed with a two-fold cut-off limit.  
Table S2. Overlap of genes differentially expressed with a two-fold cut-off limit for polyplexes over time.  
Table S3. Overlap of genes differentially expressed with a two-fold cut-off limit comparing polyplex gene expression profile with the lipoplex gene 
expression profile at each time point.
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Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of polyplexes. 
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression1 
2 h 201693_s_at EGR1 early growth response 1 AV733950 0.999 4.404 
 
210996_s_at YWHAE 
tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase 
activation protein, epsilon 
polypeptide 
U43430 0.995 0.474 
 
220047_at SIRT4 sirtuin 4 
NM_01224
0 
0.996 0.449 
 
242408_at STYX 
serine/threonine/tyrosine 
interacting protein 
AW968935 0.993 0.414 
 
1560760_s_at NA NA BC042056 1.000 0.345 
 
1558449_at NA NA BC040475 0.996 0.273 
 
1554785_at CCDC82 
coiled-coil domain 
containing 82 
BC018663 0.995 0.272 
 
236613_at RBM25 
RNA binding motif protein 
25 
BE466195 0.993 0.255 
 
210148_at HIPK3 
homeodomain interacting 
protein kinase 3 
AF305239 1.000 0.250 
 
238548_at NA NA AW863675 0.998 0.221 
 
214942_at RBM34 
RNA binding motif protein 
34 
D38491 1.000 0.163 
 
202988_s_at RGS1 
regulator of G-protein 
signaling 1 
NM_00292
2 
0.993 0.145 
 
1552649_a_at RFFL 
ring finger and FYVE-like 
domain containing E3 
ubiquitin protein ligase 
NM_05717
8 
0.994 0.136 
 
220224_at HAO1 
hydroxyacid oxidase 
(glycolate oxidase) 1 
NM_01754
5 
0.993 0.113 
 
239110_s_at W79643 NA W79643 0.996 0.108 
 
217547_x_at ZNF675 zinc finger protein 675 BF308250 0.998 0.103 
 
238520_at TRERF1 
transcriptional regulating 
factor 1 
BF724270 0.998 0.102 
 
232451_at AL110176 NA AL110176 0.997 0.097 
Table S1, page 2 
 
 
Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of polyplexes. 
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221030_s_at ARHGAP24 
Rho GTPase activating 
protein 24 
NM_03130
5 
1.000 0.085 
 
241790_at T57946 NA T57946 0.999 0.075 
 
1559990_at LOC283070 
uncharacterized 
LOC283070 
BQ636703 0.997 0.073 
 
1569062_s_at IQGAP3 
IQ motif containing 
GTPase activating protein 3 
BC033549 0.994 0.072 
 
210611_s_at DTNA dystrobrevin, alpha U26744 0.998 0.072 
 
1562111_at BC039439 NA BC039439 0.999 0.069 
 
209493_at PDZD2 PDZ domain containing 2 AF338650 0.997 0.067 
 
231367_s_at AW300131 NA AW300131 1.000 0.060 
 
1560028_at C11orf57 
chromosome 11 open 
reading frame 57 
AK094203 0.990 0.059 
 
234050_at TAGAP 
T-cell activation 
RhoGTPase activating 
protein 
AK025272 0.997 0.059 
 
236848_s_at TEX13A testis expressed 13A AW291477 0.996 0.051 
 
231335_at MS4A6E 
membrane-spanning 4-
domains, subfamily A, 
member 6E 
AA917066 0.999 0.050 
 
1556694_a_at AA716482 NA AA716482 0.996 0.042 
 
1561362_at AI419968 NA AI419968 0.999 0.038 
 
204205_at APOBEC3G 
apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide-like 3G 
NM_02182
2 
0.995 0.037 
 
1570290_at BC033970 NA BC033970 0.995 0.032 
 
240488_at AW444934 NA AW444934 0.992 0.029 
 
1564628_at AL049302 NA AL049302 0.998 0.028 
 
230607_at T86874 NA T86874 0.997 0.027 
 
233883_at SNX24 sorting nexin 24 AK021473 0.997 0.026 
 
216482_x_at ZNF79 zinc finger protein 79 X65232 0.997 0.025 
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1553514_a_at VNN3 vanin 3 
NM_07862
5 
0.995 0.024 
 
243714_at T97641 NA T97641 0.994 0.023 
 
227957_at GSN gelsolin BE962069 0.995 0.022 
 
241574_s_at IGF2BP1 
insulin-like growth factor 2 
mRNA binding protein 1 
H93038 0.994 0.021 
 
206651_s_at CPB2 
carboxypeptidase B2 
(plasma) 
NM_01641
3 
0.992 0.020 
 
211655_at IGLV3-25 
immunoglobulin lambda 
variable 3-25 
D01059 0.992 0.018 
 
220393_at LGSN 
lengsin, lens protein with 
glutamine synthetase 
domain 
NM_01657
1 
0.991 0.018 
 
216209_at LOC400084 
uncharacterized 
LOC400084 
AL137270 0.993 0.017 
 
231209_at EXOC3L4 
exocyst complex 
component 3-like 4 
BF511215 0.990 0.017 
 
240388_at KRT27 keratin 27 AI160083 0.992 0.014 
 
            
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
8 h 1555340_x_at RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 22.712 
 
221200_at NM_022155 NA 
NM_02215
5 
1.000 8.968 
 
1554140_at WDR78 WD repeat domain 78 BC032406 1.000 7.899 
 
238825_at ACRC acidic repeat containing AI091533 1.000 7.746 
 
205054_at NEB nebulin 
NM_00454
3 
1.000 6.446 
 
203872_at ACTA1 
actin, alpha 1, skeletal 
muscle 
NM_00110
0 
1.000 6.007 
 
214601_at TPH1 tryptophan hydroxylase 1 AI350339 1.000 5.538 
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1565830_at AL833615 NA AL833615 1.000 5.330 
 
1562209_at DCAF4L1 
DDB1 and CUL4 
associated factor 4-like 1 
BU561160 1.000 4.350 
 
1568807_a_at RBM26-AS1 
RBM26 antisense RNA 1 
(non-protein coding) 
AI301081 1.000 4.136 
 
239436_at CHORDC1 
cysteine and histidine-rich 
domain (CHORD) 
containing 1 
AI473843 1.000 3.986 
 
217609_at LRRC23 
leucine rich repeat 
containing 23 
BG420747 1.000 3.897 
 
1557104_at ZSCAN30 
zinc finger and SCAN 
domain containing 30 
AW028277 0.999 3.739 
 
241156_at AI939588 NA AI939588 1.000 3.706 
 
237058_x_at SLC6A13 
solute carrier family 6 
(neurotransmitter 
transporter, GABA), 
member 13 
AI802118 1.000 3.688 
 
231084_at WDR96 WD repeat domain 96 AW665251 1.000 3.595 
 
240089_at BF508868 NA BF508868 1.000 3.477 
 
239203_at C7orf53 
chromosome 7 open 
reading frame 53 
AW014728 1.000 3.431 
 
229323_at LOC387723 
uncharacterized 
LOC387723 
AI991561 1.000 3.401 
 
208498_s_at NM_004038 NA 
NM_00403
8 
1.000 3.307 
 
204894_s_at AOC3 
amine oxidase, copper 
containing 3 (vascular 
adhesion protein 1) 
NM_00373
4 
1.000 3.235 
 
214409_at RFPL3-AS1 
RFPL3 antisense RNA 1 
(non-protein coding) 
AL021937 1.000 3.182 
 
220703_at IDI2-AS1 
IDI2 antisense RNA 1 
(non-protein coding) 
NM_01847
0 
1.000 3.058 
 
238139_at AI810034 NA AI810034 0.999 2.993 
 
232826_at AU144129 NA AU144129 1.000 2.970 
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235803_at AA843122 NA AA843122 1.000 2.957 
 
236430_at TMED6 
transmembrane emp24 
protein transport domain 
containing 6 
AA708152 1.000 2.902 
 
222227_at AK000847 NA AK000847 1.000 2.851 
 
205940_at MYH3 
myosin, heavy chain 3, 
skeletal muscle, embryonic 
NM_00247
0 
1.000 2.827 
 
202450_s_at CTSK cathepsin K 
NM_00039
6 
1.000 2.813 
 
244497_at AI650407 NA AI650407 0.998 2.788 
 
203889_at SCG5 
secretogranin V (7B2 
protein) 
NM_00302
0 
1.000 2.783 
 
244321_at PGAP1 
post-GPI attachment to 
proteins 1 
BF063546 1.000 2.683 
 
205786_s_at ITGAM 
integrin, alpha M 
(complement component 3 
receptor 3 subunit) 
NM_00063
2 
1.000 2.660 
 
219947_at CLEC4A 
C-type lectin domain 
family 4, member A 
NM_01618
4 
1.000 2.613 
 
220623_s_at TSGA10 testis specific, 10 
NM_02524
4 
1.000 2.610 
 
214094_at FUBP1 
far upstream element 
(FUSE) binding protein 1 
AA156865 1.000 2.607 
 
227532_at LRRC39 
leucine rich repeat 
containing 39 
BF111992 1.000 2.572 
 
239845_at AI885066 NA AI885066 1.000 2.449 
 
202887_s_at DDIT4 
DNA-damage-inducible 
transcript 4 
NM_01905
8 
1.000 2.222 
 
238250_at AI911318 NA AI911318 0.999 2.202 
 
227591_at 
LOC1005056
96 
uncharacterized 
LOC100505696 
AI123416 1.000 2.201 
 
232752_at 
LOC1002876
16 
uncharacterized 
LOC100287616 
AK001164 1.000 2.194 
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205871_at BC005379 NA BC005379 1.000 2.144 
 
202672_s_at ATF3 
activating transcription 
factor 3 
NM_00167
4 
1.000 2.140 
 
221035_s_at TEX14 testis expressed 14 
NM_03127
2 
1.000 2.134 
 
225442_at DDR2 
discoidin domain receptor 
tyrosine kinase 2 
AI799915 0.999 2.117 
 
215338_s_at NKTR 
natural killer-tumor 
recognition sequence 
AI688640 0.999 0.497 
 
223113_at TMEM138 transmembrane protein 138 AF151030 0.994 0.497 
 
216169_at AK025430 NA AK025430 0.998 0.497 
 
220235_s_at LRIF1 
ligand dependent nuclear 
receptor interacting factor 1 
NM_01837
2 
0.995 0.496 
 
1565975_at AK074226 NA AK074226 0.999 0.496 
 
209311_at BCL2L2 BCL2-like 2 D87461 0.993 0.496 
 
236323_at PVRL3-AS1 
PVRL3 antisense RNA 1 
(non-protein coding) 
AI253027 0.991 0.495 
 
230388_s_at 
KANSL1-
AS1 
KANSL1 antisense RNA 1 
(non-protein coding) 
AI797017 0.998 0.494 
 
215022_x_at ZNF33B zinc finger protein 33B BG429214 0.990 0.494 
 
223420_at DNAJC14 
DnaJ (Hsp40) homolog, 
subfamily C, member 14 
AA156470 0.998 0.494 
 
224471_s_at BTRC 
beta-transducin repeat 
containing E3 ubiquitin 
protein ligase 
BC006204 0.995 0.492 
 
1555007_s_at WDR66 WD repeat domain 66 BC036233 0.997 0.491 
 
228729_at CCNB1 cyclin B1 N90191 0.999 0.489 
 
223427_s_at EPB41L4B 
erythrocyte membrane 
protein band 4.1 like 4B 
AB032179 0.996 0.489 
 
223421_at CYHR1 cysteine/histidine-rich 1 BC005073 0.991 0.482 
 
219880_at 
LOC1005076
19 
uncharacterized 
LOC100507619 
NM_02290
7 
0.994 0.480 
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212153_at POGZ 
pogo transposable element 
with ZNF domain 
AB007930 0.995 0.479 
 
223256_at G2E3 
G2/M-phase specific E3 
ubiquitin protein ligase 
AW007694 0.992 0.478 
 
236502_at AI808359 NA AI808359 0.994 0.478 
 
203863_at ACTN2 actinin, alpha 2 W63731 0.992 0.477 
 
238797_at TRIM11 
tripartite motif containing 
11 
BF059582 0.994 0.477 
 
202241_at TRIB1 
tribbles homolog 1 
(Drosophila) 
NM_02519
5 
0.999 0.477 
 
231437_at SLC35D2 
solute carrier family 35, 
member D2 
AA693722 0.996 0.477 
 
203245_s_at LINC00094 
long intergenic non-protein 
coding RNA 94 
BC002791 0.993 0.475 
 
228790_at FAM110B 
family with sequence 
similarity 110, member B 
AW264082 0.990 0.473 
 
202767_at ACP2 
acid phosphatase 2, 
lysosomal 
NM_00161
0 
0.996 0.472 
 
225203_at PPP1R16A 
protein phosphatase 1, 
regulatory subunit 16A 
AI742931 0.995 0.472 
 
206085_s_at CTH 
cystathionase 
(cystathionine gamma-
lyase) 
NM_00190
2 
0.998 0.469 
 
1565786_x_at FLJ45482 
uncharacterized 
LOC645566 
BQ953917 0.997 0.468 
 
236117_at AA706701 NA AA706701 0.990 0.466 
 
226408_at TEAD2 
TEA domain family 
member 2 
AA905942 0.990 0.465 
 
209590_at BMP7 
bone morphogenetic protein 
7 
AL157414 0.997 0.465 
 
214148_at 
LOC1005074
24 
uncharacterized 
LOC100507424 
U90917 0.992 0.462 
 
236282_at AA769100 NA AA769100 0.996 0.461 
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229069_at BF477573 NA BF477573 0.993 0.461 
 
229738_at DNAH10 
dynein, axonemal, heavy 
chain 10 
AI700446 0.992 0.460 
 
238220_at KDM6A 
lysine (K)-specific 
demethylase 6A 
BE670257 0.991 0.459 
 
222595_s_at DIDO1 death inducer-obliterator 1 AL578222 0.991 0.458 
 
219168_s_at PRR5 proline rich 5 (renal) 
NM_01770
1 
0.993 0.457 
 
203778_at MANBA 
mannosidase, beta A, 
lysosomal 
NM_00590
8 
0.996 0.457 
 
232284_at AI206345 NA AI206345 0.990 0.454 
 
230328_at BF057656 NA BF057656 0.993 0.454 
 
230215_at SEC61A2 
Sec61 alpha 2 subunit (S. 
cerevisiae) 
AK022640 0.994 0.452 
 
202545_at PRKCD protein kinase C, delta 
NM_00625
4 
0.992 0.452 
 
217010_s_at CDC25C 
cell division cycle 25 
homolog C (S. pombe) 
AF277724 0.991 0.450 
 
243683_at MORF4L2 mortality factor 4 like 2 H43976 0.993 0.449 
 
226599_at FHDC1 FH2 domain containing 1 AA527080 0.991 0.449 
 
235010_at LOC729013 
uncharacterized 
LOC729013 
AA833832 0.996 0.448 
 
215786_at AK022170 NA AK022170 0.991 0.447 
 
215942_s_at GTSE1 
G-2 and S-phase expressed 
1 
BF973178 0.997 0.447 
 
225300_at C15orf23 
chromosome 15 open 
reading frame 23 
BF792864 0.998 0.446 
 
227792_at ITPRIPL2 
inositol 1,4,5-trisphosphate 
receptor interacting protein-
like 2 
AA490685 0.995 0.446 
 
221983_at FAM134A 
family with sequence 
similarity 134, member A 
AL040896 0.993 0.446 
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215008_at TLL2 tolloid-like 2 AA582404 0.999 0.445 
 
205802_at TRPC1 
transient receptor potential 
cation channel, subfamily 
C, member 1 
NM_00330
4 
0.996 0.444 
 
225675_at C14orf101 
chromosome 14 open 
reading frame 101 
AW976269 0.994 0.444 
 
227936_at TMEM68 transmembrane protein 68 AI671172 0.992 0.443 
 
229790_at TERF2 
telomeric repeat binding 
factor 2 
AW006832 0.994 0.442 
 
208763_s_at TSC22D3 
TSC22 domain family, 
member 3 
AL110191 0.996 0.442 
 
207197_at ZIC3 Zic family member 3 
NM_00341
3 
0.994 0.440 
 
243491_at AW993257 NA AW993257 0.993 0.437 
 
233841_s_at SUDS3 
suppressor of defective 
silencing 3 homolog (S. 
cerevisiae) 
AK026749 0.994 0.432 
 
227656_at C6orf70 
chromosome 6 open 
reading frame 70 
AW968493 0.996 0.432 
 
231574_at D59630 NA D59630 0.992 0.431 
 
206186_at MPP3 
membrane protein, 
palmitoylated 3 (MAGUK 
p55 subfamily member 3) 
NM_00193
2 
0.993 0.429 
 
201626_at INSIG1 insulin induced gene 1 BG292233 0.999 0.425 
 
220649_at AGBL3 
ATP/GTP binding protein-
like 3 
NM_02485
6 
0.994 0.425 
 
242601_at HEPACAM2 
HEPACAM family member 
2 
AA600175 0.997 0.424 
 
205139_s_at UST uronyl-2-sulfotransferase 
NM_00571
5 
0.992 0.423 
 
230312_at AI146812 NA AI146812 0.995 0.421 
 
242610_x_at AI569997 NA AI569997 0.991 0.420 
 
219477_s_at NM_018676 NA 
NM_01867
0.993 0.419 
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211298_s_at ALB albumin AF116645 0.997 0.419 
 
203556_at ZHX2 
zinc fingers and 
homeoboxes 2 
NM_01494
3 
0.990 0.418 
 
235681_at BE894882 NA BE894882 0.992 0.418 
 
234408_at IL17F interleukin 17F AL034343 0.992 0.417 
 
229268_at FAM105B 
family with sequence 
similarity 105, member B 
AA723152 0.992 0.409 
 
201625_s_at INSIG1 insulin induced gene 1 BE300521 0.997 0.408 
 
209431_s_at PATZ1 
POZ (BTB) and AT hook 
containing zinc finger 1 
AF254083 0.990 0.407 
 
1568706_s_at AF318328 NA AF318328 0.996 0.407 
 
235441_at BF217471 NA BF217471 0.991 0.406 
 
219647_at POPDC2 
popeye domain containing 
2 
NM_02213
5 
0.994 0.405 
 
219737_s_at PCDH9 protocadherin 9 AI524125 0.997 0.405 
 
225864_at FAM84B 
family with sequence 
similarity 84, member B 
AL039862 0.999 0.403 
 
202957_at HCLS1 
hematopoietic cell-specific 
Lyn substrate 1 
NM_00533
5 
0.998 0.402 
 
221257_x_at FBXO38 F-box protein 38 
NM_03079
3 
0.995 0.401 
 
233402_at AU159414 NA AU159414 0.990 0.400 
 
221971_x_at BE672818 NA BE672818 0.990 0.397 
 
214569_at IFNA5 interferon, alpha 5 
NM_00216
9 
0.997 0.396 
 
228655_at BE466077 NA BE466077 0.995 0.395 
 
206268_at LEFTY1 
left-right determination 
factor 1 
NM_02099
7 
0.990 0.394 
 
1560899_at H50121 NA H50121 0.998 0.391 
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232803_at FLJ31958 
uncharacterized 
LOC143153 
H09470 0.991 0.391 
 
209733_at MID2 midline 2 AL034399 0.990 0.390 
 
244872_at RBBP4 
retinoblastoma binding 
protein 4 
BE514107 0.996 0.388 
 
1569021_at PIK3C2A 
phosphoinositide-3-kinase, 
class 2, alpha polypeptide 
BC040952 0.994 0.387 
 
1570394_at XRN1 5'-3' exoribonuclease 1 BC039314 0.998 0.385 
 
224688_at C7orf42 
chromosome 7 open 
reading frame 42 
BE962299 0.994 0.383 
 
238571_at BF055200 NA BF055200 0.991 0.383 
 
209902_at ATR 
ataxia telangiectasia and 
Rad3 related 
U49844 0.993 0.379 
 
200632_s_at NDRG1 
N-myc downstream 
regulated 1 
NM_00609
6 
0.995 0.372 
 
1555411_a_at CCNL1 cyclin L1 AF367476 0.990 0.372 
 
207826_s_at ID3 
inhibitor of DNA binding 3, 
dominant negative helix-
loop-helix protein 
NM_00216
7 
0.992 0.371 
 
229447_x_at N32025 NA N32025 1.000 0.369 
 
212168_at RBM12 
RNA binding motif protein 
12 
AL514547 0.998 0.369 
 
217779_s_at NM_017761 NA 
NM_01776
1 
0.996 0.366 
 
202302_s_at RSRC2 
arginine/serine-rich coiled-
coil 2 
NM_02301
2 
0.998 0.360 
 
205085_at ORC1 
origin recognition complex, 
subunit 1 
NM_00415
3 
0.990 0.358 
 
203378_at PCF11 
PCF11, cleavage and 
polyadenylation factor 
subunit, homolog (S. 
cerevisiae) 
AB020631 0.993 0.355 
 
203178_at GATM glycine amidinotransferase 
(L-arginine:glycine 
NM_00148
2 
0.999 0.353 
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amidinotransferase) 
 
239477_at EFHB 
EF-hand domain family, 
member B 
BF941046 0.996 0.347 
 
222760_at ZNF703 zinc finger protein 703 BG290193 0.998 0.345 
 
209464_at AURKB aurora kinase B AB011446 0.993 0.341 
 
209806_at HIST1H2BK histone cluster 1, H2bk BC000893 0.999 0.339 
 
226740_x_at BF740216 NA BF740216 1.000 0.325 
 
206976_s_at HSPH1 
heat shock 105kDa/110kDa 
protein 1 
NM_00664
4 
0.993 0.322 
 
201103_x_at BE299495 NA BE299495 0.999 0.308 
 
214280_x_at HNRNPA1 
heterogeneous nuclear 
ribonucleoprotein A1 
X79536 1.000 0.302 
 
223081_at PHF23 PHD finger protein 23 BC002509 0.990 0.300 
 
203714_s_at TBCE tubulin folding cofactor E 
NM_00319
3 
0.998 0.299 
 
222700_at ATL2 atlastin GTPase 2 AV700003 0.994 0.295 
 
1560652_at AL832136 NA AL832136 0.999 0.295 
 
222162_s_at ADAMTS1 
ADAM metallopeptidase 
with thrombospondin type 
1 motif, 1 
AK023795 0.993 0.289 
 
225786_at 
HNRNPU-
AS1 
HNRNPU antisense RNA 1 
(non-protein coding) 
AI440495 0.990 0.282 
 
213612_x_at AI800419 NA AI800419 0.999 0.280 
 
1561741_at BC042016 NA BC042016 0.996 0.278 
 
212854_x_at AB051480 NA AB051480 0.997 0.251 
 
222501_s_at REPIN1 replication initiator 1 BE674760 0.991 0.250 
 
223096_at NOP58 
NOP58 ribonucleoprotein 
homolog (yeast) 
AF161469 0.997 0.237 
 
203213_at CDK1 cyclin-dependent kinase 1 AL524035 0.990 0.236 
 
209974_s_at BUB3 budding uninhibited by 
benzimidazoles 3 homolog 
AF047473 0.997 0.219 
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(yeast) 
 
218009_s_at PRC1 
protein regulator of 
cytokinesis 1 
NM_00398
1 
0.991 0.200 
 
204170_s_at CKS2 
CDC28 protein kinase 
regulatory subunit 2 
NM_00182
7 
0.992 0.162 
 
            
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
16 h 
1555339_at RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 13.198 
 
239436_at CHORDC1 
cysteine and histidine-rich 
domain (CHORD) 
containing 1 
AI473843 1.000 9.356 
 
221200_at NM_022155 NA 
NM_02215
5 
1.000 7.509 
 
205054_at NEB nebulin 
NM_00454
3 
1.000 7.321 
 
1554140_at WDR78 WD repeat domain 78 BC032406 1.000 6.286 
 
203872_at ACTA1 
actin, alpha 1, skeletal 
muscle 
NM_00110
0 
1.000 5.475 
 
238825_at ACRC acidic repeat containing AI091533 1.000 5.421 
 
244321_at PGAP1 
post-GPI attachment to 
proteins 1 
BF063546 1.000 5.263 
 
1565830_at AL833615 NA AL833615 1.000 5.245 
 
208498_s_at NM_004038 NA 
NM_00403
8 
1.000 4.453 
 
203889_at SCG5 
secretogranin V (7B2 
protein) 
NM_00302
0 
1.000 4.450 
 
214601_at TPH1 tryptophan hydroxylase 1 AI350339 1.000 4.181 
 
231084_at WDR96 WD repeat domain 96 AW665251 1.000 4.046 
 
1554980_a_at ATF3 
activating transcription 
factor 3 
AB066566 1.000 3.962 
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236430_at TMED6 
transmembrane emp24 
protein transport domain 
containing 6 
AA708152 0.996 3.827 
 
1568807_a_at RBM26-AS1 
RBM26 antisense RNA 1 
(non-protein coding) 
AI301081 1.000 3.821 
 
238139_at AI810034 NA AI810034 1.000 3.819 
 
1561759_at LOC645513 
uncharacterized 
LOC645513 
AF085995 1.000 3.616 
 
239203_at C7orf53 
chromosome 7 open 
reading frame 53 
AW014728 1.000 3.600 
 
237058_x_at SLC6A13 
solute carrier family 6 
(neurotransmitter 
transporter, GABA), 
member 13 
AI802118 1.000 3.419 
 
239282_at CCDC41 
coiled-coil domain 
containing 41 
AI651679 1.000 3.405 
 
214409_at RFPL3-AS1 
RFPL3 antisense RNA 1 
(non-protein coding) 
AL021937 0.999 3.385 
 
244497_at AI650407 NA AI650407 1.000 3.328 
 
217609_at LRRC23 
leucine rich repeat 
containing 23 
BG420747 1.000 3.251 
 
232826_at AU144129 NA AU144129 1.000 3.229 
 
220346_at MTHFD2L 
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 2-like 
NM_02500
1 
1.000 3.224 
 
210941_at PCDH7 protocadherin 7 AB006756 1.000 3.215 
 
205871_at BC005379 NA BC005379 1.000 3.213 
 
214138_at ZNF79 zinc finger protein 79 AA284829 0.998 3.203 
 
241156_at AI939588 NA AI939588 1.000 3.164 
 
205940_at MYH3 
myosin, heavy chain 3, 
skeletal muscle, embryonic 
NM_00247
0 
1.000 3.122 
 
216250_s_at LPXN leupaxin X77598 0.998 2.991 
 
221035_s_at TEX14 testis expressed 14 
NM_03127
1.000 2.987 
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2 
 
1555476_at IREB2 
iron-responsive element 
binding protein 2 
BC017880 0.996 2.891 
 
227301_at BE644816 NA BE644816 1.000 2.858 
 
229323_at LOC387723 
uncharacterized 
LOC387723 
AI991561 1.000 2.807 
 
219947_at CLEC4A 
C-type lectin domain 
family 4, member A 
NM_01618
4 
0.999 2.797 
 
235803_at AA843122 NA AA843122 1.000 2.787 
 
206512_at NM_005083 NA 
NM_00508
3 
0.999 2.785 
 
227532_at LRRC39 
leucine rich repeat 
containing 39 
BF111992 0.999 2.785 
 
238158_at MEIG1 
meiosis expressed gene 1 
homolog (mouse) 
BF509612 0.999 2.782 
 
1553759_at MCM9 
minichromosome 
maintenance complex 
component 9 
NM_15325
5 
1.000 2.775 
 
229170_s_at TTC18 
tetratricopeptide repeat 
domain 18 
AW024437 1.000 2.773 
 
238250_at AI911318 NA AI911318 0.996 2.768 
 
214094_at FUBP1 
far upstream element 
(FUSE) binding protein 1 
AA156865 1.000 2.755 
 
232641_at ZNF596 zinc finger protein 596 AC004908 1.000 2.733 
 
204894_s_at AOC3 
amine oxidase, copper 
containing 3 (vascular 
adhesion protein 1) 
NM_00373
4 
1.000 2.731 
 
203455_s_at SAT1 
spermidine/spermine N1-
acetyltransferase 1 
NM_00297
0 
0.999 2.707 
 
202450_s_at CTSK cathepsin K 
NM_00039
6 
1.000 2.707 
 
236097_at AA442776 NA AA442776 1.000 2.705 
 
220623_s_at TSGA10 testis specific, 10 
NM_02524
0.997 2.704 
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4 
 
1554293_at TTBK2 tau tubulin kinase 2 BC041876 1.000 2.675 
 
214748_at N4BP2L2 
NEDD4 binding protein 2-
like 2 
U50529 0.998 2.651 
 
243581_at AW117229 NA AW117229 0.999 2.620 
 
240089_at BF508868 NA BF508868 1.000 2.614 
 
214415_at N58120 NA N58120 0.997 2.611 
 
223908_at HDAC8 histone deacetylase 8 AF212246 1.000 2.596 
 
205786_s_at ITGAM 
integrin, alpha M 
(complement component 3 
receptor 3 subunit) 
NM_00063
2 
0.995 2.594 
 
225077_at CHD2 
chromodomain helicase 
DNA binding protein 2 
AA890703 1.000 2.586 
 
211298_s_at ALB albumin AF116645 0.999 2.579 
 
213570_at EIF4E2 
eukaryotic translation 
initiation factor 4E family 
member 2 
BF516289 1.000 2.572 
 
207757_at ZFP2 
zinc finger protein 2 
homolog (mouse) 
NM_03061
3 
1.000 2.547 
 
240319_at AI023795 NA AI023795 0.999 2.544 
 
216733_s_at GATM 
glycine amidinotransferase 
(L-arginine:glycine 
amidinotransferase) 
X86401 1.000 2.538 
 
209911_x_at HIST1H2BD histone cluster 1, H2bd BC002842 0.998 2.515 
 
232753_at ZNF346 zinc finger protein 346 AU147613 1.000 2.481 
 
1552634_a_at ZNF101 zinc finger protein 101 
NM_03320
4 
0.999 2.450 
 
240206_at TARS threonyl-tRNA synthetase AA701890 0.996 2.449 
 
230683_at W56760 NA W56760 0.999 2.440 
 
207201_s_at SLC22A1 
solute carrier family 22 
(organic cation transporter), 
member 1 
NM_00305
7 
1.000 2.409 
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230292_at AA868809 NA AA868809 0.998 2.397 
 
231382_at FGF18 fibroblast growth factor 18 AI798863 0.999 2.377 
 
1560973_a_at AF086424 NA AF086424 0.996 2.374 
 
220148_at ALDH8A1 
aldehyde dehydrogenase 8 
family, member A1 
NM_02256
8 
0.996 2.365 
 
222019_at PFDN6 prefoldin subunit 6 AW007185 0.996 2.354 
 
228234_at AI423165 NA AI423165 0.999 2.354 
 
230535_s_at ATP5E 
ATP synthase, H+ 
transporting, mitochondrial 
F1 complex, epsilon 
subunit 
BF109387 0.998 2.348 
 
242656_at GTF2H1 
general transcription factor 
IIH, polypeptide 1, 62kDa 
AI377688 0.999 2.347 
 
1554038_at LARP1B 
La ribonucleoprotein 
domain family, member 1B 
BC030516 1.000 2.341 
 
202887_s_at DDIT4 
DNA-damage-inducible 
transcript 4 
NM_01905
8 
0.995 2.339 
 
1569022_a_at PIK3C2A 
phosphoinositide-3-kinase, 
class 2, alpha polypeptide 
BC040952 0.999 2.321 
 
229130_at AU145323 NA AU145323 0.998 2.320 
 
1552326_a_at CCDC11 
coiled-coil domain 
containing 11 
NM_14502
0 
1.000 2.320 
 
239845_at AI885066 NA AI885066 1.000 2.316 
 
222227_at AK000847 NA AK000847 1.000 2.309 
 
218371_s_at PSPC1 paraspeckle component 1 
NM_01828
2 
0.992 2.297 
 
240834_at FAM105B 
family with sequence 
similarity 105, member B 
AI813337 0.999 2.296 
 
242586_at FSD1L 
fibronectin type III and 
SPRY domain containing 
1-like 
H07986 1.000 2.280 
 
210910_s_at POMZP3 POM121 and ZP3 fusion BC000487 0.999 2.266 
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225442_at DDR2 
discoidin domain receptor 
tyrosine kinase 2 
AI799915 0.999 2.262 
 
210077_s_at SRSF5 
serine/arginine-rich splicing 
factor 5 
U30884 0.997 2.258 
 
236213_at AI809760 NA AI809760 1.000 2.255 
 
227963_at BF515913 NA BF515913 0.999 2.253 
 
1559397_s_at PRR14 proline rich 14 BE788667 0.999 2.245 
 
206110_at HIST1H3H histone cluster 1, H3h 
NM_00353
6 
0.999 2.244 
 
207623_at ABCF2 
ATP-binding cassette, sub-
family F (GCN20), member 
2 
NM_00569
2 
0.993 2.241 
 
229754_at 
LOC1005072
97 
uncharacterized 
LOC100507297 
AW104619 0.999 2.234 
 
229627_at AI831514 NA AI831514 1.000 2.230 
 
1557104_at ZSCAN30 
zinc finger and SCAN 
domain containing 30 
AW028277 0.996 2.229 
 
232196_at LCA5L 
Leber congenital amaurosis 
5-like 
AI825840 0.999 2.226 
 
235540_at GNRH1 
gonadotropin-releasing 
hormone 1 (luteinizing-
releasing hormone) 
AW296153 0.994 2.223 
 
228736_at HELQ helicase, POLQ-like AW084661 0.997 2.219 
 
224989_at AI824013 NA AI824013 0.997 2.218 
 
239434_at T78087 NA T78087 0.999 2.213 
 
1569157_s_at ZNF846 zinc finger protein 846 BC037359 0.998 2.210 
 
1556062_at RPP30 
ribonuclease P/MRP 30kDa 
subunit 
AW182934 0.997 2.205 
 
1568696_at CDNF 
cerebral dopamine 
neurotrophic factor 
BC037872 0.997 2.194 
 
220444_at ZNF557 zinc finger protein 557 
NM_02434
1 
0.991 2.190 
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244066_at DENND4C 
DENN/MADD domain 
containing 4C 
N34297 0.999 2.187 
 
214683_s_at AI251890 NA AI251890 0.999 2.183 
 
235535_x_at AI369073 NA AI369073 0.996 2.177 
 
243802_at DNAH12 
dynein, axonemal, heavy 
chain 12 
AI005163 0.999 2.165 
 
207064_s_at AOC2 
amine oxidase, copper 
containing 2 (retina-
specific) 
NM_00959
0 
1.000 2.163 
 
203862_s_at ACTN2 actinin, alpha 2 H16245 0.998 2.159 
 
243378_at BE673747 NA BE673747 0.998 2.159 
 
227172_at TMEM116 transmembrane protein 116 BC000282 0.999 2.149 
 
242754_at AW132066 NA AW132066 1.000 2.148 
 
236892_s_at HOXB-AS3 
HOXB cluster antisense 
RNA 3 (non-protein 
coding) 
BF590528 0.994 2.148 
 
208107_s_at LOC81691 exonuclease NEF-sp 
NM_03094
1 
1.000 2.147 
 
1557417_s_at AA844689 NA AA844689 0.999 2.143 
 
213124_at ZNF473 zinc finger protein 473 BG538800 0.990 2.143 
 
242708_at BF224430 NA BF224430 0.999 2.142 
 
229962_at LRRC37A3 
leucine rich repeat 
containing 37, member A3 
W68731 0.993 2.142 
 
242051_at AI695695 NA AI695695 0.999 2.141 
 
215819_s_at N53959 NA N53959 0.997 2.129 
 
239797_at AA503877 NA AA503877 0.995 2.122 
 
237127_at AA142959 NA AA142959 0.997 2.119 
 
239248_at 
LOC1005074
95 
uncharacterized 
LOC100507495 
BE742802 0.999 2.093 
 
235033_at NPEPL1 aminopeptidase-like 1 AL577823 0.996 2.087 
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230120_s_at PLGLB2 plasminogen-like B2 AI088455 0.998 2.085 
 
217555_at SMC1A 
structural maintenance of 
chromosomes 1A 
AI042030 0.999 2.081 
 
209292_at ID4 
inhibitor of DNA binding 4, 
dominant negative helix-
loop-helix protein 
AL022726 1.000 2.081 
 
203665_at HMOX1 
heme oxygenase 
(decycling) 1 
NM_00213
3 
1.000 2.076 
 
214950_at L39064 NA L39064 0.997 2.072 
 
206862_at ZNF254 zinc finger protein 254 
NM_00487
6 
0.999 2.071 
 
235608_at AI863194 NA AI863194 0.999 2.069 
 
230355_at SEPT7P2 septin 7 pseudogene 2 BF445841 0.996 2.065 
 
222953_at GPR83 
G protein-coupled receptor 
83 
BE670361 0.999 2.063 
 
1570394_at XRN1 5'-3' exoribonuclease 1 BC039314 0.999 2.062 
 
231095_at 
LOC1005070
49 
uncharacterized 
LOC100507049 
AW193811 0.998 2.060 
 
220064_at TTC21B 
tetratricopeptide repeat 
domain 21B 
NM_02475
3 
0.999 2.060 
 
222680_s_at DTL 
denticleless E3 ubiquitin 
protein ligase homolog 
(Drosophila) 
AK001261 1.000 2.060 
 
208958_at ERP44 
endoplasmic reticulum 
protein 44 
AI827677 0.999 2.048 
 
49452_at ACACB 
acetyl-CoA carboxylase 
beta 
AI057637 0.999 2.042 
 
238528_at UBR1 
ubiquitin protein ligase E3 
component n-recognin 1 
AI361043 0.992 2.040 
 
208118_x_at NM_031211 NA 
NM_03121
1 
0.999 2.039 
 
213557_at CDK12 cyclin-dependent kinase 12 AW305119 0.998 2.022 
 
1568787_at 
LOC1005060 uncharacterized 
R64146 1.000 2.021 
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83 LOC100506083 
 
230657_at AI423466 NA AI423466 0.998 2.020 
 
238094_at AW292905 NA AW292905 0.994 2.016 
 
1559509_at R17062 NA R17062 0.994 2.012 
 
228124_at ABHD12 
abhydrolase domain 
containing 12 
AW303865 0.998 2.010 
 
223825_at KIAA1432 KIAA1432 AL136875 1.000 2.010 
 
229628_s_at AI831514 NA AI831514 0.999 2.001 
 
1569867_at EME2 
essential meiotic 
endonuclease 1 homolog 2 
(S. pombe) 
BC041011 0.996 0.499 
 
229318_at BF509796 NA BF509796 0.999 0.491 
 
242715_at AA331548 NA AA331548 0.999 0.444 
 
            
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
24 h 
1555339_at RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 14.588 
 
239436_at CHORDC1 
cysteine and histidine-rich 
domain (CHORD) 
containing 1 
AI473843 1.000 10.948 
 
1554140_at WDR78 WD repeat domain 78 BC032406 1.000 8.779 
 
244321_at PGAP1 
post-GPI attachment to 
proteins 1 
BF063546 1.000 7.703 
 
221200_at NM_022155 NA 
NM_02215
5 
1.000 6.654 
 
205054_at NEB nebulin 
NM_00454
3 
1.000 6.589 
 
203889_at SCG5 
secretogranin V (7B2 
protein) 
NM_00302
0 
1.000 6.151 
 
238825_at ACRC acidic repeat containing AI091533 1.000 6.144 
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202672_s_at ATF3 
activating transcription 
factor 3 
NM_00167
4 
1.000 5.834 
 
1555476_at IREB2 
iron-responsive element 
binding protein 2 
BC017880 1.000 5.714 
 
241156_at AI939588 NA AI939588 1.000 5.105 
 
203872_at ACTA1 
actin, alpha 1, skeletal 
muscle 
NM_00110
0 
1.000 5.041 
 
221035_s_at TEX14 testis expressed 14 
NM_03127
2 
1.000 4.540 
 
231084_at WDR96 WD repeat domain 96 AW665251 1.000 4.468 
 
1565830_at AL833615 NA AL833615 1.000 4.439 
 
209911_x_at HIST1H2BD histone cluster 1, H2bd BC002842 1.000 4.374 
 
205940_at MYH3 
myosin, heavy chain 3, 
skeletal muscle, embryonic 
NM_00247
0 
1.000 4.353 
 
214409_at RFPL3-AS1 
RFPL3 antisense RNA 1 
(non-protein coding) 
AL021937 1.000 4.300 
 
232826_at AU144129 NA AU144129 1.000 4.171 
 
236430_at TMED6 
transmembrane emp24 
protein transport domain 
containing 6 
AA708152 1.000 4.151 
 
237058_x_at SLC6A13 
solute carrier family 6 
(neurotransmitter 
transporter, GABA), 
member 13 
AI802118 1.000 4.100 
 
214138_at ZNF79 zinc finger protein 79 AA284829 1.000 4.045 
 
220346_at MTHFD2L 
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 2-like 
NM_02500
1 
1.000 3.982 
 
1557104_at ZSCAN30 
zinc finger and SCAN 
domain containing 30 
AW028277 1.000 3.975 
 
210941_at PCDH7 protocadherin 7 AB006756 1.000 3.863 
 
243581_at AW117229 NA AW117229 1.000 3.844 
 
232753_at ZNF346 zinc finger protein 346 AU147613 1.000 3.809 
Table S1, page 23 
 
 
Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of polyplexes. 
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression1 
 
205871_at BC005379 NA BC005379 1.000 3.762 
 
216250_s_at LPXN leupaxin X77598 1.000 3.714 
 
238139_at AI810034 NA AI810034 1.000 3.677 
 
206512_at NM_005083 NA 
NM_00508
3 
1.000 3.536 
 
227296_at MFSD3 
major facilitator 
superfamily domain 
containing 3 
AA523543 1.000 3.406 
 
219947_at CLEC4A 
C-type lectin domain 
family 4, member A 
NM_01618
4 
1.000 3.366 
 
225442_at DDR2 
discoidin domain receptor 
tyrosine kinase 2 
AI799915 1.000 3.349 
 
1569022_a_at PIK3C2A 
phosphoinositide-3-kinase, 
class 2, alpha polypeptide 
BC040952 1.000 3.231 
 
227301_at BE644816 NA BE644816 1.000 3.222 
 
1568807_a_at RBM26-AS1 
RBM26 antisense RNA 1 
(non-protein coding) 
AI301081 1.000 3.154 
 
235803_at AA843122 NA AA843122 1.000 3.121 
 
207623_at ABCF2 
ATP-binding cassette, sub-
family F (GCN20), member 
2 
NM_00569
2 
1.000 3.103 
 
1562209_at DCAF4L1 
DDB1 and CUL4 
associated factor 4-like 1 
BU561160 1.000 3.070 
 
1561759_at LOC645513 
uncharacterized 
LOC645513 
AF085995 1.000 3.003 
 
222851_at ZNF654 zinc finger protein 654 AL120354 1.000 3.002 
 
216009_at SLC39A9 
solute carrier family 39 
(zinc transporter), member 
9 
U92027 1.000 2.931 
 
229170_s_at TTC18 
tetratricopeptide repeat 
domain 18 
AW024437 1.000 2.926 
 
214094_at FUBP1 
far upstream element 
(FUSE) binding protein 1 
AA156865 1.000 2.910 
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239944_at AA431379 NA AA431379 1.000 2.905 
 
1559509_at R17062 NA R17062 1.000 2.903 
 
217373_x_at MDM2 
Mdm2, p53 E3 ubiquitin 
protein ligase homolog 
(mouse) 
AJ276888 1.000 2.902 
 
214748_at N4BP2L2 
NEDD4 binding protein 2-
like 2 
U50529 1.000 2.874 
 
239203_at C7orf53 
chromosome 7 open 
reading frame 53 
AW014728 1.000 2.849 
 
235033_at NPEPL1 aminopeptidase-like 1 AL577823 1.000 2.832 
 
239794_at AI356405 NA AI356405 1.000 2.797 
 
209383_at DDIT3 
DNA-damage-inducible 
transcript 3 
BC003637 1.000 2.780 
 
242656_at GTF2H1 
general transcription factor 
IIH, polypeptide 1, 62kDa 
AI377688 1.000 2.757 
 
208498_s_at NM_004038 NA 
NM_00403
8 
0.996 2.739 
 
209315_at HBS1L HBS1-like (S. cerevisiae) AW297143 1.000 2.639 
 
201939_at PLK2 polo-like kinase 2 
NM_00662
2 
1.000 2.602 
 
236613_at RBM25 
RNA binding motif protein 
25 
BE466195 0.999 2.582 
 
220148_at ALDH8A1 
aldehyde dehydrogenase 8 
family, member A1 
NM_02256
8 
1.000 2.572 
 
238528_at UBR1 
ubiquitin protein ligase E3 
component n-recognin 1 
AI361043 1.000 2.559 
 
213418_at HSPA6 
heat shock 70kDa protein 6 
(HSP70B') 
NM_00215
5 
1.000 2.500 
 
225077_at CHD2 
chromodomain helicase 
DNA binding protein 2 
AA890703 1.000 2.495 
 
228532_at C1orf162 
chromosome 1 open 
reading frame 162 
AW662189 1.000 2.409 
 
217609_at LRRC23 
leucine rich repeat 
BG420747 1.000 2.394 
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227532_at LRRC39 
leucine rich repeat 
containing 39 
BF111992 1.000 2.372 
 
242838_at MAP6D1 MAP6 domain containing 1 AA283642 1.000 2.366 
 
210077_s_at SRSF5 
serine/arginine-rich splicing 
factor 5 
U30884 1.000 2.341 
 
229072_at BF968097 NA BF968097 1.000 2.314 
 
223908_at HDAC8 histone deacetylase 8 AF212246 1.000 2.252 
 
218371_s_at PSPC1 paraspeckle component 1 
NM_01828
2 
1.000 2.243 
 
244497_at AI650407 NA AI650407 1.000 2.227 
 
214601_at TPH1 tryptophan hydroxylase 1 AI350339 1.000 2.208 
 
235608_at AI863194 NA AI863194 1.000 2.203 
 
218504_at FAHD2A 
fumarylacetoacetate 
hydrolase domain 
containing 2A 
NM_01604
4 
1.000 2.198 
 
1557078_at SLFN5 schlafen family member 5 AK054668 1.000 2.198 
 
241668_s_at AI033967 NA AI033967 1.000 2.191 
 
239797_at AA503877 NA AA503877 1.000 2.149 
 
214792_x_at VAMP2 
vesicle-associated 
membrane protein 2 
(synaptobrevin 2) 
AI955119 1.000 2.143 
 
1569157_s_at ZNF846 zinc finger protein 846 BC037359 1.000 2.127 
 
237020_at CATSPERD 
catsper channel auxiliary 
subunit delta 
AI203106 1.000 2.125 
 
215228_at NHLH2 nescient helix loop helix 2 AA166895 1.000 2.123 
 
240910_at BF431313 NA BF431313 1.000 2.119 
 
228234_at AI423165 NA AI423165 1.000 2.116 
 
1552634_a_at ZNF101 zinc finger protein 101 
NM_03320
4 
1.000 2.094 
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1556090_at BM970306 NA BM970306 1.000 2.083 
 
202450_s_at CTSK cathepsin K 
NM_00039
6 
1.000 2.082 
 
207183_at GPR19 
G protein-coupled receptor 
19 
NM_00614
3 
1.000 2.063 
 
1553759_at MCM9 
minichromosome 
maintenance complex 
component 9 
NM_15325
5 
0.997 2.041 
 
1557196_a_at AL831886 NA AL831886 1.000 2.033 
 
231487_at COX8C 
cytochrome c oxidase 
subunit VIIIC 
AW269746 1.000 2.004 
 
204711_at KIAA0753 KIAA0753 
NM_01480
4 
0.999 0.500 
 
37028_at PPP1R15A 
protein phosphatase 1, 
regulatory subunit 15A 
U83981 0.994 0.500 
 
227212_s_at PHF19 PHD finger protein 19 BE544837 0.999 0.499 
 
202146_at IFRD1 
interferon-related 
developmental regulator 1 
AA747426 0.997 0.498 
 
222044_at PCIF1 
PDX1 C-terminal inhibiting 
factor 1 
AI199589 0.994 0.497 
 
1554116_s_at PARP11 
poly (ADP-ribose) 
polymerase family, member 
11 
BC031073 0.993 0.497 
 
229153_at SLC7A6OS 
solute carrier family 7, 
member 6 opposite strand 
BF432635 0.999 0.496 
 
221096_s_at TMCO6 
transmembrane and coiled-
coil domains 6 
NM_01850
2 
0.996 0.495 
 
239816_at POLD3 
polymerase (DNA-
directed), delta 3, accessory 
subunit 
AW337142 0.999 0.494 
 
242720_at ITIH4 
inter-alpha-trypsin inhibitor 
heavy chain family, 
member 4 
AI004137 0.995 0.493 
 
205244_s_at SLC13A3 
solute carrier family 13 
(sodium-dependent 
dicarboxylate transporter), 
NM_02282
9 
0.993 0.493 
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227689_at ZNF227 zinc finger protein 227 BF739795 0.994 0.492 
 
210396_s_at AF271775 NA AF271775 0.999 0.492 
 
1569307_s_at BC038430 NA BC038430 0.999 0.492 
 
221270_s_at QTRT1 
queuine tRNA-
ribosyltransferase 1 
NM_03120
9 
0.996 0.492 
 
218743_at CHMP6 
charged multivesicular 
body protein 6 
NM_02459
1 
0.999 0.491 
 
217555_at SMC1A 
structural maintenance of 
chromosomes 1A 
AI042030 0.998 0.491 
 
209488_s_at RBPMS 
RNA binding protein with 
multiple splicing 
D84109 0.997 0.490 
 
32062_at LRRC14 
leucine rich repeat 
containing 14 
D25216 0.996 0.490 
 
212338_at MYO1D myosin ID AA621962 0.992 0.490 
 
51200_at C19orf60 
chromosome 19 open 
reading frame 60 
AI744084 0.998 0.490 
 
225417_at EPC1 
enhancer of polycomb 
homolog 1 (Drosophila) 
AA766646 0.999 0.489 
 
1555902_at ARMCX5 
armadillo repeat containing, 
X-linked 5 
BC022066 0.993 0.488 
 
218280_x_at NM_003516 NA 
NM_00351
6 
0.998 0.488 
 
207163_s_at AKT1 
v-akt murine thymoma viral 
oncogene homolog 1 
NM_00516
3 
0.993 0.487 
 
230522_s_at C9orf100 
chromosome 9 open 
reading frame 100 
BG028209 0.997 0.487 
 
221267_s_at FAM108A1 
family with sequence 
similarity 108, member A1 
NM_03121
3 
0.996 0.487 
 
222563_s_at TNKS2 
tankyrase, TRF1-interacting 
ankyrin-related ADP-ribose 
polymerase 2 
AF329696 0.995 0.486 
 
212563_at BOP1 block of proliferation 1 BG491842 0.998 0.486 
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225779_at SLC27A4 
solute carrier family 27 
(fatty acid transporter), 
member 4 
AK000722 0.998 0.485 
 
204019_s_at SH3YL1 
SH3 domain containing, 
Ysc84-like 1 (S. cerevisiae) 
NM_01567
7 
0.993 0.485 
 
218023_s_at FAM53C 
family with sequence 
similarity 53, member C 
NM_01660
5 
0.999 0.485 
 
239737_at AW028687 NA AW028687 0.997 0.484 
 
235581_at AA478537 NA AA478537 0.998 0.484 
 
222028_at ZNF45 zinc finger protein 45 AI967981 0.999 0.484 
 
218875_s_at FBXO5 F-box protein 5 
NM_01217
7 
0.997 0.484 
 
237923_at AI733801 NA AI733801 0.999 0.483 
 
236926_at TBX1 T-box 1 AW074836 0.994 0.482 
 
205647_at RAD52 
RAD52 homolog (S. 
cerevisiae) 
NM_00287
9 
0.995 0.482 
 
238999_at AI610347 NA AI610347 0.996 0.482 
 
210273_at PCDH7 protocadherin 7 AB006757 0.999 0.482 
 
214395_x_at EEF1D 
eukaryotic translation 
elongation factor 1 delta 
(guanine nucleotide 
exchange protein) 
AI335509 0.991 0.481 
 
203163_at KATNB1 
katanin p80 (WD repeat 
containing) subunit B 1 
NM_00588
6 
0.999 0.481 
 
229833_at 
LOC1005067
13 
uncharacterized 
LOC100506713 
BF507533 0.996 0.480 
 
228642_at BF593636 NA BF593636 1.000 0.479 
 
209568_s_at RGL1 
ral guanine nucleotide 
dissociation stimulator-like 
1 
AF186779 0.998 0.479 
 
236999_at AA767131 NA AA767131 0.995 0.479 
 
1558750_a_at 
LOC1002886
37 
OTU domain containing 7A 
pseudogene 
BG109249 0.996 0.478 
Table S1, page 29 
 
 
Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of polyplexes. 
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression1 
 
230591_at LOC729887 
uncharacterized 
LOC729887 
AI792242 0.997 0.478 
 
238333_s_at SPRN 
shadow of prion protein 
homolog (zebrafish) 
AI355435 0.992 0.478 
 
219958_at TMEM74B transmembrane protein 74B 
NM_01835
4 
0.996 0.478 
 
222998_at MAF1 
MAF1 homolog (S. 
cerevisiae) 
AL136937 0.998 0.477 
 
227864_s_at FAM125A 
family with sequence 
similarity 125, member A 
AI091713 0.999 0.476 
 
208763_s_at TSC22D3 
TSC22 domain family, 
member 3 
AL110191 1.000 0.476 
 
225616_at SPRYD4 SPRY domain containing 4 AI570493 0.997 0.476 
 
217734_s_at WDR6 WD repeat domain 6 
NM_01803
1 
0.999 0.475 
 
202814_s_at HEXIM1 
hexamethylene bis-
acetamide inducible 1 
AW193511 1.000 0.475 
 
217551_at OR7E14P 
olfactory receptor, family 7, 
subfamily E, member 14 
pseudogene 
AA719797 0.997 0.474 
 
209553_at VPS8 
vacuolar protein sorting 8 
homolog (S. cerevisiae) 
BC001001 0.999 0.473 
 
211721_s_at ZNF551 zinc finger protein 551 BC005868 0.995 0.473 
 
202393_s_at KLF10 Kruppel-like factor 10 
NM_00565
5 
0.996 0.472 
 
219722_s_at GDPD3 
glycerophosphodiester 
phosphodiesterase domain 
containing 3 
NM_02430
7 
0.992 0.472 
 
223500_at CPLX1 complexin 1 BC002471 0.995 0.470 
 
222408_s_at YPEL5 yippee-like 5 (Drosophila) BC000836 0.997 0.469 
 
225951_s_at AV756026 NA AV756026 1.000 0.467 
 
1556645_s_at BC043400 NA BC043400 0.995 0.465 
 
220746_s_at UIMC1 
ubiquitin interaction motif NM_01629
0.999 0.465 
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218479_s_at XPO4 exportin 4 
NM_02245
9 
0.999 0.464 
 
201834_at PRKAB1 
protein kinase, AMP-
activated, beta 1 non-
catalytic subunit 
BC001007 0.993 0.464 
 
225675_at C14orf101 
chromosome 14 open 
reading frame 101 
AW976269 0.994 0.462 
 
200974_at ACTA2 
actin, alpha 2, smooth 
muscle, aorta 
NM_00161
3 
0.990 0.462 
 
225860_at BG469257 NA BG469257 0.999 0.461 
 
224763_at RPL37 ribosomal protein L37 BF724210 0.999 0.461 
 
49679_s_at MMP24 
matrix metallopeptidase 24 
(membrane-inserted) 
AA243774 0.997 0.460 
 
1569108_a_at ZNF589 zinc finger protein 589 BC028160 0.997 0.460 
 
229574_at TRA2A 
transformer 2 alpha 
homolog (Drosophila) 
AI268231 0.993 0.460 
 
222138_s_at WDR13 WD repeat domain 13 AF158978 0.997 0.460 
 
229954_at CHDH choline dehydrogenase AI025415 0.996 0.459 
 
210869_s_at MCAM 
melanoma cell adhesion 
molecule 
M29277 0.995 0.459 
 
239834_at AW874669 NA AW874669 0.995 0.459 
 
227859_at DNAJC27 
DnaJ (Hsp40) homolog, 
subfamily C, member 27 
AV706343 0.998 0.459 
 
1556339_a_at BM353142 NA BM353142 0.997 0.458 
 
230835_at KRTDAP 
keratinocyte differentiation-
associated protein 
W69083 0.994 0.458 
 
204862_s_at NME3 
non-metastatic cells 3, 
protein expressed in 
NM_00251
3 
0.999 0.458 
 
41512_at BRAP BRCA1 associated protein AL042733 0.998 0.457 
 
238035_at SP3 Sp3 transcription factor N66313 0.992 0.456 
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226576_at ARHGAP26 
Rho GTPase activating 
protein 26 
AI768563 0.994 0.456 
 
225605_at TP53I13 
tumor protein p53 inducible 
protein 13 
AL540867 0.998 0.455 
 
218526_s_at RANGRF 
RAN guanine nucleotide 
release factor 
NM_01418
5 
1.000 0.455 
 
224798_s_at C15orf17 
chromosome 15 open 
reading frame 17 
AI079857 0.998 0.454 
 
228001_at TMEM50B transmembrane protein 50B N51405 0.991 0.454 
 
238491_at 
LOC1005061
61 
uncharacterized 
LOC100506161 
BF241692 0.998 0.453 
 
204793_at GPRASP1 
G protein-coupled receptor 
associated sorting protein 1 
NM_01471
0 
0.992 0.452 
 
1557224_at BM682057 NA BM682057 0.995 0.452 
 
1553564_at MACROD2 
MACRO domain 
containing 2 
NM_08067
6 
0.998 0.451 
 
230154_at WAC 
WW domain containing 
adaptor with coiled-coil 
AW003119 0.993 0.451 
 
229711_s_at MDM2 
Mdm2, p53 E3 ubiquitin 
protein ligase homolog 
(mouse) 
AA902480 0.996 0.451 
 
1557410_at 
LOC1005066
06 
uncharacterized 
LOC100506606 
AK090590 0.997 0.450 
 
225477_s_at NR2C2 
nuclear receptor subfamily 
2, group C, member 2 
AL138444 0.999 0.449 
 
215519_x_at SGSM3 
small G protein signaling 
modulator 3 
AI081779 0.997 0.449 
 
219230_at TMEM100 transmembrane protein 100 
NM_01828
6 
0.995 0.449 
 
228033_at E2F7 E2F transcription factor 7 AI341146 1.000 0.448 
 
226408_at TEAD2 
TEA domain family 
member 2 
AA905942 0.994 0.448 
 
219361_s_at AEN 
apoptosis enhancing 
nuclease 
NM_02276
7 
0.996 0.448 
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228652_at ZNF776 zinc finger protein 776 AI279532 0.999 0.448 
 
227561_at DDR2 
discoidin domain receptor 
tyrosine kinase 2 
W73819 0.996 0.447 
 
204538_x_at NPIP 
nuclear pore complex 
interacting protein 
NM_00698
5 
1.000 0.447 
 
209889_at SEC31B 
SEC31 homolog B (S. 
cerevisiae) 
AF274863 0.998 0.446 
 
242316_at AI810103 NA AI810103 0.995 0.445 
 
214857_at 
LOC1005057
61 
uncharacterized 
LOC100505761 
AL050035 0.993 0.445 
 
228595_at HSD17B1 
hydroxysteroid (17-beta) 
dehydrogenase 1 
AA894611 0.998 0.445 
 
212528_at PPPDE2 
PPPDE peptidase domain 
containing 2 
AI348009 0.998 0.444 
 
233010_at AU158573 NA AU158573 0.995 0.444 
 
209751_s_at AF291676 NA AF291676 0.999 0.444 
 
1553103_at NFX1 
nuclear transcription factor, 
X-box binding 1 
NM_14713
4 
0.998 0.443 
 
214035_x_at LOC399491 
GPS, PLAT and 
transmembrane domain-
containing protein 
AA308853 1.000 0.443 
 
228816_at ATP6AP1L 
ATPase, H+ transporting, 
lysosomal accessory protein 
1-like 
AK022625 0.995 0.443 
 
244618_at W58255 NA W58255 0.995 0.442 
 
231115_at POLH 
polymerase (DNA 
directed), eta 
AI890529 0.996 0.441 
 
1556613_s_at DPY19L4 dpy-19-like 4 (C. elegans) BC038568 0.994 0.441 
 
230312_at AI146812 NA AI146812 0.999 0.441 
 
214706_at ZNF200 zinc finger protein 200 AU149447 0.999 0.441 
 
37590_g_at AL109698 NA AL109698 0.993 0.440 
 
227921_at AI797678 NA AI797678 1.000 0.440 
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235702_at AA507442 NA AA507442 0.999 0.439 
 
226647_at TMEM25 transmembrane protein 25 AL562445 0.995 0.438 
 
214121_x_at PDLIM7 
PDZ and LIM domain 7 
(enigma) 
AA086229 0.994 0.437 
 
211029_x_at FGF18 fibroblast growth factor 18 BC006245 0.995 0.437 
 
237083_at H46176 NA H46176 0.996 0.437 
 
209852_x_at PSME3 
proteasome (prosome, 
macropain) activator 
subunit 3 (PA28 gamma; 
Ki) 
BC001423 0.992 0.437 
 
221042_s_at CLMN 
calmin (calponin-like, 
transmembrane) 
NM_02473
4 
0.996 0.437 
 
202378_s_at LEPROT 
leptin receptor overlapping 
transcript 
NM_01752
6 
0.997 0.436 
 
228852_at ENSA endosulfine alpha AV726322 0.996 0.436 
 
204839_at POP5 
processing of precursor 5, 
ribonuclease P/MRP 
subunit (S. cerevisiae) 
NM_01591
8 
0.999 0.435 
 
205658_s_at SNAPC4 
small nuclear RNA 
activating complex, 
polypeptide 4, 190kDa 
NM_00308
6 
0.997 0.435 
 
220755_s_at C6orf48 
chromosome 6 open 
reading frame 48 
NM_01694
7 
1.000 0.433 
 
209509_s_at DPAGT1 
dolichyl-phosphate (UDP-
N-acetylglucosamine) N-
acetylglucosaminephosphot
ransferase 1 (GlcNAc-1-P 
transferase) 
BC000325 0.997 0.433 
 
203164_at SLC33A1 
solute carrier family 33 
(acetyl-CoA transporter), 
member 1 
BE464756 0.992 0.433 
 
212751_at UBE2N 
ubiquitin-conjugating 
enzyme E2N 
BG290646 0.997 0.432 
 
235181_at TYW5 
tRNA-yW synthesizing 
protein 5 
H12075 0.993 0.432 
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226552_at IER5L 
immediate early response 
5-like 
BF110608 0.994 0.431 
 
225698_at 
EPB41L4A-
AS1 
EPB41L4A antisense RNA 
1 (non-protein coding) 
BF314746 1.000 0.431 
 
221727_at SUB1 
SUB1 homolog (S. 
cerevisiae) 
AA456973 0.991 0.431 
 
233455_at AL110133 NA AL110133 1.000 0.431 
 
204135_at FILIP1L 
filamin A interacting 
protein 1-like 
NM_01489
0 
0.997 0.430 
 
212708_at MSL1 
male-specific lethal 1 
homolog (Drosophila) 
AV721987 0.993 0.429 
 
232274_at CCNL2 cyclin L2 AK000685 0.991 0.429 
 
40472_at LPCAT4 
lysophosphatidylcholine 
acyltransferase 4 
AF007155 0.992 0.427 
 
223692_at NMNAT1 
nicotinamide nucleotide 
adenylyltransferase 1 
AF312734 0.991 0.426 
 
33304_at ISG20 
interferon stimulated 
exonuclease gene 20kDa 
U88964 0.996 0.425 
 
223421_at CYHR1 cysteine/histidine-rich 1 BC005073 0.996 0.425 
 
1569973_at SEPT7P2 septin 7 pseudogene 2 BC015774 0.992 0.425 
 
219426_at EIF2C3 
eukaryotic translation 
initiation factor 2C, 3 
NM_02485
2 
0.997 0.424 
 
201703_s_at PPP1R10 
protein phosphatase 1, 
regulatory subunit 10 
NM_00271
4 
0.997 0.423 
 
207877_s_at NVL nuclear VCP-like 
NM_00253
3 
0.999 0.423 
 
230759_at SNX14 sorting nexin 14 AI476227 0.998 0.422 
 
212791_at C1orf216 
chromosome 1 open 
reading frame 216 
AL042729 0.995 0.422 
 
202802_at DHPS deoxyhypusine synthase 
NM_00193
0 
0.996 0.422 
 
208922_s_at NXF1 
nuclear RNA export factor 
1 
BC004904 1.000 0.421 
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203992_s_at KDM6A 
lysine (K)-specific 
demethylase 6A 
AF000992 0.997 0.421 
 
231375_at LOC202181 
chromosome 5 open 
reading frame 25 
pseudogene 
AI027731 0.991 0.418 
 
229913_at C7orf61 
chromosome 7 open 
reading frame 61 
BF940911 0.992 0.417 
 
224774_s_at NAV1 neuron navigator 1 AK022622 0.994 0.416 
 
230588_s_at LOC285074 
anaphase promoting 
complex subunit 1 
pseudogene 
AA906142 0.996 0.416 
 
229351_at AA634138 NA AA634138 0.995 0.415 
 
217630_at ANGEL2 
angel homolog 2 
(Drosophila) 
AI188346 0.997 0.414 
 
223095_at MARVELD1 
MARVEL domain 
containing 1 
BC004995 0.998 0.413 
 
223284_at NAT14 
N-acetyltransferase 14 
(GCN5-related, putative) 
AB038651 0.995 0.413 
 
214870_x_at AC002045 NA AC002045 1.000 0.413 
 
228171_s_at PLEKHG4 
pleckstrin homology 
domain containing, family 
G (with RhoGef domain) 
member 4 
AI056683 0.993 0.412 
 
1558094_s_at C3orf19 
chromosome 3 open 
reading frame 19 
AL526467 0.997 0.412 
 
207034_s_at GLI2 GLI family zinc finger 2 
NM_03037
9 
0.991 0.412 
 
237299_at T71642 NA T71642 0.995 0.411 
 
226993_at AA973551 NA AA973551 0.990 0.411 
 
228983_at AI692591 NA AI692591 0.994 0.410 
 
44111_at VPS33B 
vacuolar protein sorting 33 
homolog B (yeast) 
AI672363 0.997 0.409 
 
242568_s_at BF995452 NA BF995452 0.999 0.409 
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1554411_at CTNNB1 
catenin (cadherin-
associated protein), beta 1, 
88kDa 
AB062292 0.996 0.409 
 
219481_at TTC13 
tetratricopeptide repeat 
domain 13 
NM_02452
5 
0.998 0.408 
 
230626_at TSPAN12 tetraspanin 12 AI056699 0.991 0.408 
 
211950_at UBR4 
ubiquitin protein ligase E3 
component n-recognin 4 
AB007931 1.000 0.408 
 
204028_s_at RABGAP1 
RAB GTPase activating 
protein 1 
NM_01219
7 
0.998 0.407 
 
205339_at STIL 
SCL/TAL1 interrupting 
locus 
NM_00303
5 
0.998 0.407 
 
214100_x_at NSUN5P1 
NOP2/Sun domain family, 
member 5 pseudogene 1 
AI284845 0.993 0.407 
 
241453_at PTK2 
PTK2 protein tyrosine 
kinase 2 
AA912743 0.996 0.406 
 
218410_s_at PGP 
phosphoglycolate 
phosphatase 
NM_02411
8 
0.996 0.406 
 
213206_at GOSR2 
golgi SNAP receptor 
complex member 2 
AW149492 0.992 0.404 
 
223742_at MRPL4 
mitochondrial ribosomal 
protein L4 
BC000756 0.992 0.404 
 
210069_at U62733 NA U62733 0.995 0.403 
 
225508_at KIAA1468 KIAA1468 BF055274 0.992 0.403 
 
227755_at AA042983 NA AA042983 0.991 0.402 
 
219249_s_at FKBP10 
FK506 binding protein 10, 
65 kDa 
NM_02193
9 
0.996 0.402 
 
1555964_at ARL17A 
ADP-ribosylation factor-
like 17A 
BU623906 0.995 0.402 
 
222752_s_at TMEM206 transmembrane protein 206 AK024066 0.997 0.402 
 
228661_s_at AI768374 NA AI768374 0.992 0.401 
 
202458_at PRSS23 protease, serine, 23 
NM_00717
3 
0.997 0.401 
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238692_at BTBD11 
BTB (POZ) domain 
containing 11 
AL040935 0.992 0.400 
 
221920_s_at SLC25A37 
solute carrier family 25, 
member 37 
BE677761 0.995 0.399 
 
236750_at AL134451 NA AL134451 0.992 0.399 
 
205559_s_at PCSK5 
proprotein convertase 
subtilisin/kexin type 5 
NM_00620
0 
0.996 0.399 
 
224369_s_at FBXO38 F-box protein 38 AF251055 0.993 0.398 
 
231638_at PRSS30P 
protease, serine, 30 
homolog (mouse), 
pseudogene 
AA400057 0.991 0.396 
 
1556429_a_at WDR67 WD repeat domain 67 BC026969 0.995 0.395 
 
209020_at C20orf111 
chromosome 20 open 
reading frame 111 
AF217514 0.994 0.394 
 
213951_s_at PSMC3IP PSMC3 interacting protein BE964655 0.997 0.394 
 
218348_s_at ZC3H7A 
zinc finger CCCH-type 
containing 7A 
NM_01415
3 
0.994 0.394 
 
225434_at DEDD2 
death effector domain 
containing 2 
AW245401 0.997 0.393 
 
225864_at FAM84B 
family with sequence 
similarity 84, member B 
AL039862 0.999 0.393 
 
234929_s_at SPATA7 
spermatogenesis associated 
7 
AF144488 0.991 0.393 
 
214821_at SLC25A4 
solute carrier family 25 
(mitochondrial carrier; 
adenine nucleotide 
translocator), member 4 
AF052119 0.993 0.392 
 
223290_at BC000320 NA BC000320 0.994 0.392 
 
201009_s_at TXNIP 
thioredoxin interacting 
protein 
AI439556 0.994 0.391 
 
221723_s_at SLC4A5 
solute carrier family 4, 
sodium bicarbonate 
cotransporter, member 5 
AF243499 0.994 0.390 
 
203782_s_at POLRMT polymerase (RNA) 
mitochondrial (DNA 
NM_00503
0.994 0.390 
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directed) 5 
 
205277_at PRDM2 
PR domain containing 2, 
with ZNF domain 
NM_01223
1 
0.995 0.390 
 
203739_at ZNF217 zinc finger protein 217 
NM_00652
6 
0.990 0.390 
 
236080_at 
LOC1005076
70 
uncharacterized 
LOC100507670 
BE276063 0.992 0.389 
 
236330_at AW292996 NA AW292996 0.990 0.387 
 
218083_at PTGES2 prostaglandin E synthase 2 
NM_02507
2 
0.996 0.386 
 
223706_at C22orf23 
chromosome 22 open 
reading frame 23 
AF324466 0.991 0.385 
 
216264_s_at LAMB2 laminin, beta 2 (laminin S) X79683 0.996 0.383 
 
212858_at PAQR4 
progestin and adipoQ 
receptor family member IV 
AL520675 0.994 0.383 
 
238653_at LRIG2 
leucine-rich repeats and 
immunoglobulin-like 
domains 2 
BF967997 0.994 0.382 
 
219914_at ECEL1 
endothelin converting 
enzyme-like 1 
NM_00482
6 
0.994 0.382 
 
208132_x_at PRRC2A proline-rich coiled-coil 2A 
NM_00463
8 
0.990 0.382 
 
225070_at NUS1 
nuclear undecaprenyl 
pyrophosphate synthase 1 
homolog (S. cerevisiae) 
BF112132 0.992 0.381 
 
225819_at TBRG1 
transforming growth factor 
beta regulator 1 
AA576946 0.994 0.381 
 
1555062_s_at GTPBP3 
GTP binding protein 3 
(mitochondrial) 
AY078987 0.995 0.380 
 
218858_at DEPTOR 
DEP domain containing 
MTOR-interacting protein 
NM_02278
3 
0.993 0.380 
 
202645_s_at MEN1 
multiple endocrine 
neoplasia I 
NM_00024
4 
0.994 0.380 
 
203916_at NDST2 N-deacetylase/N-
sulfotransferase (heparan 
NM_00363
0.992 0.379 
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glucosaminyl) 2 5 
 
205106_at NM_014221 NA 
NM_01422
1 
0.996 0.378 
 
227412_at PPP1R3E 
protein phosphatase 1, 
regulatory subunit 3E 
AK024489 0.993 0.378 
 
226954_at UBE2R2 
ubiquitin-conjugating 
enzyme E2R 2 
BE221883 0.997 0.378 
 
224489_at KANSL1 
KAT8 regulatory NSL 
complex subunit 1 
BC006271 0.991 0.377 
 
214280_x_at HNRNPA1 
heterogeneous nuclear 
ribonucleoprotein A1 
X79536 1.000 0.377 
 
206510_at SIX2 SIX homeobox 2 AF332197 0.995 0.376 
 
201395_at RBM5 
RNA binding motif protein 
5 
NM_00577
8 
1.000 0.376 
 
232230_at LINC00263 
long intergenic non-protein 
coding RNA 263 
AU151788 0.992 0.376 
 
223450_s_at COG3 
component of oligomeric 
golgi complex 3 
AF332595 0.993 0.374 
 
65630_at TMEM80 transmembrane protein 80 AI742455 0.992 0.374 
 
217983_s_at RNASET2 ribonuclease T2 
NM_00373
0 
0.999 0.372 
 
200617_at MLEC malectin 
NM_01473
0 
0.996 0.372 
 
215469_at AF339807 NA AF339807 0.992 0.372 
 
230130_at AI692523 NA AI692523 0.996 0.372 
 
202241_at TRIB1 
tribbles homolog 1 
(Drosophila) 
NM_02519
5 
0.992 0.372 
 
238797_at TRIM11 
tripartite motif containing 
11 
BF059582 0.993 0.371 
 
202131_s_at RIOK3 RIO kinase 3 (yeast) 
NM_00383
1 
0.992 0.371 
 
222029_x_at PFDN6 prefoldin subunit 6 
NM_01426
0 
0.997 0.370 
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227922_x_at LOC441124 
uncharacterized 
LOC441124 
AA156779 0.992 0.369 
 
225360_at TRABD TraB domain containing AL449244 0.993 0.368 
 
1556646_at AA714835 NA AA714835 0.996 0.366 
 
218243_at RUFY1 
RUN and FYVE domain 
containing 1 
NM_02515
8 
0.998 0.366 
 
224915_x_at ZNFX1-AS1 
ZNFX1 antisense RNA 1 
(non-protein coding) 
AV756131 0.997 0.366 
 
1560577_at BC031948 NA BC031948 0.993 0.365 
 
201037_at PFKP 
phosphofructokinase, 
platelet 
NM_00262
7 
0.992 0.363 
 
209556_at NCDN neurochondrin AB011179 0.993 0.363 
 
221261_x_at NM_030801 NA 
NM_03080
1 
0.991 0.362 
 
228559_at CENPN centromere protein N BF111626 0.990 0.362 
 
218897_at TMEM177 transmembrane protein 177 
NM_03057
7 
0.998 0.362 
 
227718_at PURB 
purine-rich element binding 
protein B 
BF337790 0.996 0.362 
 
216297_at AL049314 NA AL049314 0.996 0.362 
 
226080_at SSH2 
slingshot homolog 2 
(Drosophila) 
BE676214 0.995 0.360 
 
217508_s_at C18orf25 
chromosome 18 open 
reading frame 25 
BE783279 0.997 0.360 
 
238155_at AI638235 NA AI638235 0.993 0.359 
 
228245_s_at OVOS2 ovostatin 2 AW594320 0.996 0.359 
 
220201_at RC3H2 
ring finger and CCCH-type 
domains 2 
NM_01883
5 
0.995 0.358 
 
242222_at LOC440894 
uncharacterized 
LOC440894 
AA069120 0.990 0.357 
 
218073_s_at TMEM48 transmembrane protein 48 
NM_01808
7 
0.994 0.357 
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221436_s_at CDCA3 
cell division cycle 
associated 3 
NM_03129
9 
0.994 0.356 
 
218683_at PTBP2 
polypyrimidine tract 
binding protein 2 
NM_02119
0 
0.993 0.356 
 
213053_at HAUS5 
HAUS augmin-like 
complex, subunit 5 
AW189966 0.992 0.355 
 
230063_at ZNF264 zinc finger protein 264 BF063192 0.990 0.355 
 
203500_at GCDH 
glutaryl-CoA 
dehydrogenase 
NM_00015
9 
0.993 0.355 
 
209301_at CA2 carbonic anhydrase II M36532 0.999 0.354 
 
218378_s_at PRKRIP1 
PRKR interacting protein 1 
(IL11 inducible) 
NM_02465
3 
0.992 0.353 
 
225264_at RARS2 
arginyl-tRNA synthetase 2, 
mitochondrial 
AK023550 0.997 0.352 
 
212194_s_at TM9SF4 
transmembrane 9 
superfamily protein 
member 4 
AI418892 0.996 0.352 
 
226987_at RBM15B 
RNA binding motif protein 
15B 
W68720 0.990 0.352 
 
1557293_at LOC440993 
uncharacterized 
LOC440993 
CA418406 0.993 0.350 
 
201828_x_at FAM127A 
family with sequence 
similarity 127, member A 
NM_00392
8 
0.995 0.348 
 
209480_at HLA-DQB1 
major histocompatibility 
complex, class II, DQ beta 
1 
M16276 0.991 0.346 
 
229430_at C8orf46 
chromosome 8 open 
reading frame 46 
AI421311 0.998 0.345 
 
224986_s_at PDPK1 
3-phosphoinositide 
dependent protein kinase-1 
AL040394 0.993 0.345 
 
239477_at EFHB 
EF-hand domain family, 
member B 
BF941046 0.999 0.345 
 
203384_s_at GOLGA1 golgin A1 
NM_00207
7 
0.990 0.345 
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243092_at PAN3-AS1 
PAN3 antisense RNA 1 
(non-protein coding) 
AI140189 0.995 0.344 
 
52005_at WIZ 
widely interspaced zinc 
finger motifs 
AA422049 0.993 0.343 
 
1555897_at KDM1A 
lysine (K)-specific 
demethylase 1A 
CA306222 0.998 0.343 
 
230641_at AI792670 NA AI792670 0.993 0.343 
 
39817_s_at C6orf108 
chromosome 6 open 
reading frame 108 
AF040105 0.996 0.342 
 
244360_at FBXL17 
F-box and leucine-rich 
repeat protein 17 
AW002273 0.991 0.342 
 
202402_s_at CARS cysteinyl-tRNA synthetase 
NM_00175
1 
0.995 0.341 
 
204992_s_at PFN2 profilin 2 
NM_00262
8 
1.000 0.340 
 
1558693_s_at C1orf85 
chromosome 1 open 
reading frame 85 
AW090182 0.994 0.339 
 
224447_s_at MIEN1 
migration and invasion 
enhancer 1 
BC006006 0.997 0.339 
 
225462_at TMEM128 transmembrane protein 128 AV705805 0.995 0.337 
 
202109_at ARFIP2 
ADP-ribosylation factor 
interacting protein 2 
NM_01240
2 
0.993 0.336 
 
200688_at SF3B3 
splicing factor 3b, subunit 
3, 130kDa 
D13642 0.991 0.334 
 
229231_at H04996 NA H04996 0.992 0.334 
 
218257_s_at UGGT1 
UDP-glucose glycoprotein 
glucosyltransferase 1 
NM_02012
0 
0.992 0.334 
 
214984_at AC003007 NA AC003007 0.990 0.333 
 
223613_at UQCR11 
ubiquinol-cytochrome c 
reductase, complex III 
subunit XI 
BC000462 0.994 0.332 
 
200800_s_at NM_005345 NA 
NM_00534
5 
1.000 0.332 
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213365_at ERI2 
ERI1 exoribonuclease 
family member 2 
N64622 0.992 0.331 
 
224627_at GBA2 
glucosidase, beta (bile acid) 
2 
AB046825 0.995 0.331 
 
219647_at POPDC2 
popeye domain containing 
2 
NM_02213
5 
0.997 0.330 
 
204366_s_at GTF3C2 
general transcription factor 
IIIC, polypeptide 2, beta 
110kDa 
NM_00152
1 
0.997 0.329 
 
225458_at PP7080 uncharacterized LOC25845 BF528646 0.991 0.327 
 
223773_s_at SNHG12 
small nucleolar RNA host 
gene 12 (non-protein 
coding) 
AF277181 0.994 0.325 
 
204454_at LDOC1 
leucine zipper, down-
regulated in cancer 1 
NM_01231
7 
0.993 0.324 
 
218059_at ZNF706 zinc finger protein 706 
NM_01609
6 
0.995 0.322 
 
233413_at AU156421 NA AU156421 0.997 0.317 
 
230483_at AA868500 NA AA868500 0.991 0.315 
 
211038_s_at CROCCP2 
ciliary rootlet coiled-coil, 
rootletin pseudogene 2 
BC006312 0.997 0.312 
 
235099_at CMTM8 
CKLF-like MARVEL 
transmembrane domain 
containing 8 
AW080832 0.991 0.312 
 
212429_s_at GTF3C2 
general transcription factor 
IIIC, polypeptide 2, beta 
110kDa 
AW194657 0.995 0.312 
 
220587_s_at MLST8 
MTOR associated protein, 
LST8 homolog (S. 
cerevisiae) 
NM_02237
2 
0.993 0.310 
 
225310_at RBMX 
RNA binding motif protein, 
X-linked 
AI928344 1.000 0.310 
 
1553329_at C7orf45 
chromosome 7 open 
reading frame 45 
BC017587 0.997 0.308 
 
229980_s_at SNX5 sorting nexin 5 AA131508 0.999 0.305 
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228357_at UNK 
unkempt homolog 
(Drosophila) 
BE966979 0.996 0.303 
 
231142_at BF221525 NA BF221525 0.991 0.302 
 
212510_at GPD1L 
glycerol-3-phosphate 
dehydrogenase 1-like 
AA135522 0.995 0.300 
 
212689_s_at KDM3A 
lysine (K)-specific 
demethylase 3A 
AA524505 0.995 0.300 
 
213842_x_at NSUN5P2 
NOP2/Sun domain family, 
member 5 pseudogene 2 
AK021688 0.996 0.299 
 
219639_x_at PARP6 
poly (ADP-ribose) 
polymerase family, member 
6 
NM_02021
3 
0.994 0.299 
 
1559186_at PRKXP1 
protein kinase, X-linked, 
pseudogene 1 
AL833178 0.993 0.297 
 
225890_at C20orf72 
chromosome 20 open 
reading frame 72 
AI678096 0.994 0.294 
 
226829_at AFAP1L2 
actin filament associated 
protein 1-like 2 
AW138743 0.994 0.292 
 
206858_s_at HOXC6 homeobox C6 
NM_00450
3 
0.997 0.290 
 
224841_x_at GAS5 
growth arrest-specific 5 
(non-protein coding) 
BF316352 1.000 0.286 
 
228882_at TUB tubby homolog (mouse) AL042088 0.995 0.286 
 
216058_s_at CYP2C19 
cytochrome P450, family 2, 
subfamily C, polypeptide 
19 
X65962 0.994 0.278 
 
207826_s_at ID3 
inhibitor of DNA binding 3, 
dominant negative helix-
loop-helix protein 
NM_00216
7 
0.998 0.275 
 
201520_s_at GRSF1 
G-rich RNA sequence 
binding factor 1 
BF034561 0.995 0.270 
 
209265_s_at METTL3 methyltransferase like 3 BC001650 0.998 0.269 
 
208705_s_at EIF5 
eukaryotic translation 
initiation factor 5 
BG481972 1.000 0.268 
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1560652_at AL832136 NA AL832136 1.000 0.262 
 
213302_at PFAS 
phosphoribosylformylglyci
namidine synthase 
AL044326 0.996 0.262 
 
1553494_at TDH L-threonine dehydrogenase 
NM_15256
6 
0.997 0.261 
 
221730_at COL5A2 collagen, type V, alpha 2 
NM_00039
3 
0.997 0.260 
 
216199_s_at MAP3K4 
mitogen-activated protein 
kinase kinase kinase 4 
AL109942 0.991 0.256 
 
209218_at SQLE squalene epoxidase AF098865 0.998 0.249 
 
201046_s_at RAD23A 
RAD23 homolog A (S. 
cerevisiae) 
NM_00505
3 
0.995 0.243 
 
218300_at C16orf53 
chromosome 16 open 
reading frame 53 
NM_02451
6 
0.990 0.243 
 
209849_s_at RAD51C 
RAD51 homolog C (S. 
cerevisiae) 
AF029669 0.995 0.234 
 
235547_at N4BP2L2 
NEDD4 binding protein 2-
like 2 
BG548427 0.993 0.234 
 
201959_s_at MYCBP2 
MYC binding protein 2, E3 
ubiquitin protein ligase 
AA488899 0.995 0.232 
 
1570296_at BC029614 NA BC029614 0.996 0.230 
 
211996_s_at BG256504 NA BG256504 0.993 0.230 
 
220356_at CORIN corin, serine peptidase 
NM_00658
7 
0.995 0.225 
 
210774_s_at NCOA4 
nuclear receptor coactivator 
4 
AL162047 0.993 0.220 
 
212455_at YTHDC1 YTH domain containing 1 N36997 0.994 0.211 
 
243605_at AW627671 NA AW627671 0.996 0.194 
 
224610_at AL530869 NA AL530869 0.997 0.187 
 
220864_s_at NDUFA13 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 13 
NM_01596
5 
0.994 0.179 
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Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of polyplexes. 
Time 
Point 
Affy  Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression1 
 
221874_at KIAA1324 KIAA1324 AB037745 0.993 0.176 
 
210371_s_at RBBP4 
retinoblastoma binding 
protein 4 
BC003092 0.991 0.175 
 
212108_at FAF2 
Fas associated factor family 
member 2 
AB020694 0.990 0.175 
 
218594_at HEATR1 HEAT repeat containing 1 
NM_01807
2 
0.992 0.173 
 
220649_at AGBL3 
ATP/GTP binding protein-
like 3 
NM_02485
6 
0.996 0.161 
 
212643_at MAPK1IP1L 
mitogen-activated protein 
kinase 1 interacting protein 
1-like 
AI671747 0.996 0.154 
 
200881_s_at DNAJA1 
DnaJ (Hsp40) homolog, 
subfamily A, member 1 
NM_00153
9 
0.996 0.146 
 
225547_at SNHG6 
small nucleolar RNA host 
gene 6 (non-protein coding) 
BG169443 0.997 0.131 
 
200912_s_at EIF4A2 
eukaryotic translation 
initiation factor 4A2 
NM_00196
7 
0.996 0.116 
 
200893_at TRA2B 
transformer 2 beta homolog 
(Drosophila) 
NM_00459
3 
0.998 0.106 
 
200884_at CKB creatine kinase, brain 
NM_00182
3 
0.991 0.102 
 
AFFX-
HSAC07/X00
351_3_at 
ACTB actin, beta 
AFFX-
HSAC07/X
00351_3 
0.995 0.066 
 
1553551_s_at ND2 MTND2 
NM_17370
9 
0.998 0.056 
 
224373_s_at AF253979 NA AF253979 0.997 0.053 
1Differential expression represents comparison of microarray gene expression from cells treated with complexes (n = 
3) to microarray gene expression from cells left untreated (n = 3). 2Differential expression represents comparison of 
microarray gene expression from cells treated and transfection (GFP+; n = 3) to microarray gene expression from cells 
treated and untransfected (GFP-; n = 3. Differential expression greater than or less than 1 represents upregulation or 
downregulation, respectively. 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
BUB3 N53959 VAMP2 ITGAM ID3 UBR1 RAP1A 
AK022170 HMOX1 ZNF45 BF508868 AGBL3 MTHFD2L CHORDC1 
AF318328 ZNF473 PFKP DDIT4 DCAF4L1 BE644816 AU144129 
DNAJC14 HIST1H3H TMCO6 FAM105B EFHB GTF2H1 ZSCAN30 
AI569997 NM_031211 C1orf85 AI885066 TRIM11 AA503877 ATF3 
EPB41L4B AF086424 HSD17B1 TSGA10 TSC22D3 CHD2 LRRC23 
BF055200 GPR83 AEN XRN1 KDM6A MCM9 PGAP1 
RBM12 CCDC11 CMTM8 AK000847 TEAD2 N4BP2L2 ACRC 
LRIF1 MEIG1 C7orf45 AOC3 CYHR1 NPEPL1 AI810034 
CCNB1 ID4 AI033967 LOC387723 AI146812 ALDH8A1 BC005379 
G2E3 AI831514 PGP ALB RBBP4 PCDH7 RBM26-AS1 
TMEM68 CDK12 MRPL4 AI911318 AL832136 PFDN6 AI939588 
LOC100507619 PLGLB2 GAS5 GATM FBXO38 ZNF346 FUBP1 
NM_017761 AA142959 AV756026 ACTN2 TRIB1 HDAC8 PIK3C2A 
AI800419 CCDC41 MSL1 
 
HNRNPA1 FGF18 WDR96 
BF057656 ZNF596 UQCR11 
 
POPDC2 ABCF2 MYH3 
BF217471 AI251890 PPP1R15A 
 
C14orf101 R17062 C7orf53 
CCNL1 LOC100507495 BG256504 
 
FAM84B SMC1A AI650407 
TBCE DNAH12 AL530869 
  
LPXN TPH1 
FLJ45482 ABHD12 NM_014221 
  
TTC18 CLEC4A 
ATL2 N58120 AW292996 
  
IREB2 SLC6A13 
ADAMTS1 LRRC37A3 UGGT1 
  
AI423165 ACTA1 
PCF11 L39064 MEN1 
  
HIST1H2BD RFPL3-AS1 
LOC100507424 LOC100507297 PFAS 
  
ZNF101 CTSK 
NDRG1 TMEM116 ND2 
  
PSPC1 TMED6 
FAM134A AA844689 SLC33A1 
  
SRSF5 WDR78 
C6orf70 AI369073 SLC25A37 
  
NM_005083 DDR2 
PRC1 LARP1B TRABD 
  
AI863194 TEX14 
IDI2-AS1 TTBK2 AA714835 
  
AW117229 SCG5 
CDK1 AI809760 BRAP 
  
SEPT7P2 LRRC39 
BTRC POMZP3 SSH2 
  
ZNF846 NEB 
IL17F ZFP2 TSPAN12 
  
LOC645513 NM_004038 
ZHX2 BE673747 MAF1 
   
AL833615 
BE894882 ERP44 PLK2 
   
NM_022155 
NM_018676 LCA5L NUS1 
   
AA843122 
ORC1 TTC21B AA634138 
    
SLC35D2 AI023795 C20orf111 
    
N32025 TARS NMNAT1 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
BF740216 BF509796 EPB41L4A-AS1 
   
LOC729013 EIF4E2 RAD23A 
    
POGZ SLC22A1 AFAP1L2 
    
BE299495 AA442776 CDCA3 
    
D59630 LOC100506083 PDLIM7 
    
BC042016 DTL CYP2C19 
    
ATR BF515913 AL049314 
    
LOC100505696 LOC100507049 PAN3-AS1 
    
PATZ1 AI423466 UBE2R2 
    
C7orf42 GNRH1 BC043400 
    
CDC25C ZNF254 PRDM2 
    
ACP2 AI824013 BC000320 
    
BE672818 DENND4C OR7E14P 
    
BCL2L2 T78087 AI692523 
    
TMEM138 ACACB AW627671 
    
DIDO1 AI695695 EIF5 
    
PRKCD CDNF SH3YL1 
    
H50121 BF224430 C6orf108 
    
ITPRIPL2 EME2 C8orf46 
    
NKTR W56760 MDM2 
    
PRR5 AU145323 KATNB1 
    
NOP58 AW132066 BF431313 
    
DNAH10 AW292905 ZC3H7A 
    
HIST1H2BK ATP5E LOC729887 
    
HSPH1 KIAA1432 TRA2B 
    
LEFTY1 ZNF557 STIL 
    
AK025430 FSD1L SLC25A4 
    
AURKB PRR14 ARMCX5 
    
PCDH9 RPP30 DHPS 
    
FHDC1 LOC81691 SNX5 
    
MORF4L2 AOC2 ZNF706 
    
MPP3 SAT1 EEF1D 
    
TLL2 AA331548 NDST2 
    
BF477573 HELQ AA868500 
    
AA706701 HOXB-AS3 PLEKHG4 
    
TERF2 AA868809 AI638235 
    
AB051480 
 
TYW5 
    
AI206345 
 
BOP1 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
SUDS3 
 
SPRN 
    
RSRC2 
 
DDIT3 
    
AI808359 
 
C1orf216 
    
BMP7 
 
GDPD3 
    
MANBA 
 
PTK2 
    
PPP1R16A 
 
LOC100506606 
   
UST 
 
MYCBP2 
    
CTH 
 
WIZ 
    
HEPACAM2 
 
NM_003516 
    
AW993257 
 
SPRYD4 
    
TRPC1 
 
U62733 
    
IFNA5 
 
FAHD2A 
    
LOC100287616 
 
CKB 
    
AK074226 
 
ENSA 
    
C15orf23 
 
KIAA1324 
    
SEC61A2 
 
BF593636 
    
ZNF703 
 
W58255 
    
BE466077 
 
CPLX1 
    
AU159414 
 
AI610347 
    
AA769100 
 
QTRT1 
    
ZIC3 
 
SEC31B 
    
FAM110B 
 
TMEM50B 
    
GTSE1 
 
SLC27A4 
    
MID2 
 
NCDN 
    
PVRL3-AS1 
 
C7orf61 
    
FLJ31958 
 
ZNF589 
    
INSIG1 
 
LOC202181 
    
REPIN1 
 
AF339807 
    
LINC00094 
 
TRA2A 
    
WDR66 
 
PP7080 
    
HNRNPU-AS1 
 
LPCAT4 
    
CKS2 
 
PPP1R3E 
    
PHF23 
 
GPR19 
    
HCLS1 
 
AA507442 
    
KANSL1-AS1 
 
NAV1 
    
ZNF33B 
 
DNAJC27 
    
  
RGL1 
    
  
PSMC3IP 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
AU158573 
    
  
CORIN 
    
  
BTBD11 
    
  
CA2 
    
  
PRSS23 
    
  
GTPBP3 
    
  
ZNFX1-AS1 
    
  
MLST8 
    
  
ISG20 
    
  
TMEM177 
    
  
RBM5 
    
  
WDR6 
    
  
ECEL1 
    
  
PRKRIP1 
    
  
NM_030801 
    
  
BF995452 
    
  
ZNF227 
    
  
TMEM74B 
    
  
COG3 
    
  
BC029614 
    
  
AL134451 
    
  
FBXL17 
    
  
BG469257 
    
  
AW874669 
    
  
CARS 
    
  
NR2C2 
    
  
HLA-DQB1 
    
  
AA767131 
    
  
FAM108A1 
    
  
MAP3K4 
    
  
GRSF1 
    
  
AA431379 
    
  
KIAA1468 
    
  
RBPMS 
    
  
PRRC2A 
    
  
AI810103 
    
  
NPIP 
    
  
CROCCP2 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
GOLGA1 
    
  
UBE2N 
    
  
C3orf19 
    
  
H04996 
    
  
HEXIM1 
    
  
GPRASP1 
    
  
AF291676 
    
  
PARP11 
    
  
WDR67 
    
  
PAQR4 
    
  
POLH 
    
  
RC3H2 
    
  
BC031948 
    
  
PTGES2 
    
  
FILIP1L 
    
  
ACTB 
    
  
PFN2 
    
  
BF968097 
    
  
H46176 
    
  
UIMC1 
    
  
TMEM25 
    
  
COX8C 
    
  
GOSR2 
    
  
SP3 
    
  
HAUS5 
    
  
DEPTOR 
    
  
C18orf25 
    
  
KDM1A 
    
  
CHMP6 
    
  
NDUFA13 
    
  
POLRMT 
    
  
TP53I13 
    
  
NVL 
    
  
LEPROT 
    
  
CCNL2 
    
  
TTC13 
    
  
AF253979 
    
  
GLI2 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
LOC100506161 
   
  
TMEM128 
    
  
SNAPC4 
    
  
ATP6AP1L 
    
  
SLC4A5 
    
  
ANGEL2 
    
  
RBMX 
    
  
TNKS2 
    
  
KRTDAP 
    
  
MARVELD1 
    
  
MLEC 
    
  
PURB 
    
  
SUB1 
    
  
AI733801 
    
  
LAMB2 
    
  
NFX1 
    
  
NHLH2 
    
  
LOC100505761 
   
  
YPEL5 
    
  
AI797678 
    
  
AA478537 
    
  
FKBP10 
    
  
HBS1L 
    
  
RANGRF 
    
  
PTBP2 
    
  
COL5A2 
    
  
SIX2 
    
  
RNASET2 
    
  
C19orf60 
    
  
RARS2 
    
  
UNK 
    
  
C9orf100 
    
  
AU156421 
    
  
RAD52 
    
  
SNHG12 
    
  
TBRG1 
    
  
LOC285074 
    
  
AKT1 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
PHF19 
    
  
SLC39A9 
    
  
TM9SF4 
    
  
HSPA6 
    
  
ZNF264 
    
  
AI768374 
    
  
PDPK1 
    
  
EIF4A2 
    
  
SNHG6 
    
  
TDH 
    
  
LOC399491 
    
  
XPO4 
    
  
PCSK5 
    
  
DPY19L4 
    
  
DNAJA1 
    
  
PRSS30P 
    
  
MAP6D1 
    
  
PRKAB1 
    
  
SQLE 
    
  
RAD51C 
    
  
PARP6 
    
  
CTNNB1 
    
  
RABGAP1 
    
  
KIAA0753 
    
  
FBXO5 
    
  
IER5L 
    
  
ZNF654 
    
  
SLFN5 
    
  
POP5 
    
  
LOC100507670 
   
  
C6orf48 
    
  
ZNF217 
    
  
OVOS2 
    
  
KANSL1 
    
  
FAM53C 
    
  
AL109698 
    
  
VPS33B 
    
  
TBX1 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
SLC7A6OS 
    
  
AL110133 
    
  
RBM15B 
    
  
EIF2C3 
    
  
AC002045 
    
  
CATSPERD 
    
  
LOC100288637 
   
  
CHDH 
    
  
TUB 
    
  
DEDD2 
    
  
AI692591 
    
  
MCAM 
    
  
ACTA2 
    
  
C20orf72 
    
  
LINC00263 
    
  
NM_005345 
    
  
BF221525 
    
  
CLMN 
    
  
AL831886 
    
  
BM353142 
    
  
POLD3 
    
  
PPP1R10 
    
  
HOXC6 
    
  
ZNF551 
    
  
ARHGAP26 
    
  
TMEM48 
    
  
AF271775 
    
  
SLC13A3 
    
  
CENPN 
    
  
KLF10 
    
  
WDR13 
    
  
PSME3 
    
  
ERI2 
    
  
NXF1 
    
  
NME3 
    
  
RIOK3 
    
  
NSUN5P1 
    
  
ARL17A 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
LOC441124 
    
  
MACROD2 
    
  
DPAGT1 
    
  
FAM127A 
    
  
PPPDE2 
    
  
METTL3 
    
  
EPC1 
    
  
TMEM80 
    
  
RUFY1 
    
  
YTHDC1 
    
  
SGSM3 
    
  
PRKXP1 
    
  
LDOC1 
    
  
KDM3A 
    
  
AI356405 
    
  
C22orf23 
    
  
MYO1D 
    
  
MIEN1 
    
  
SNX14 
    
  
ARFIP2 
    
  
BM970306 
    
  
E2F7 
    
  
GTF3C2 
    
  
C15orf17 
    
  
WAC 
    
  
AW028687 
    
  
GPD1L 
    
  
RPL37 
    
  
IFRD1 
    
  
NCOA4 
    
  
BM682057 
    
  
LRRC14 
    
  
UBR4 
    
  
ITIH4 
    
  
MAPK1IP1L 
    
  
TXNIP 
    
  
ZNF776 
    
  
SF3B3 
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Table S2. Overlapping genes between time points (from Figure 2). 
 
8h 
(112 genes) 
16 h 
(74 genes) 
24h 
(369 genes) 
8h U 16h 
(14 genes)1 
8h U 24h 
(18 genes) 1 
16h U 24h 
(32 genes) 1 
8h U 16h U 
24h 
(35 genes) 1 
  
FAM125A 
    
  
FAF2 
    
  
SPATA7 
    
  
T71642 
    
  
NSUN5P2 
    
  
LRIG2 
    
  
C1orf162 
    
  
AA042983 
    
  
TMEM206 
    
  
AC003007 
    
  
HEATR1 
    
  
VPS8 
    
  
GCDH 
    
  
MMP24 
    
  
C16orf53 
    
  
LOC440894 
    
  
TMEM100 
    
  
LOC440993 
    
  
ZNF200 
    
  
BC038430 
    
  
GBA2 
    
  
MFSD3 
    
  
AA973551 
    
  
AI792670 
    
  
PCIF1 
    
  
LOC100506713 
   
  
NAT14 
    
1U stands for the union of the time points, e.g. a gene that was found at multiple time points. 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
C20orf96 T97641 
 
NDUFA10 AK025430 RAP1A ZNF548 ZNF596 
AK000847 
(ZNF236)  
ACTB RAP1A 
INSL3 TAGAP 
 
PACSIN3 CDK1 ATF3 KRTAP19-1 TARS RAP1A 
 
PFN2 HSPA6 
LOC1001309
38 
ZNF675 
 
ARMC8 AURKB 
 
AA457019 AI023795 
NM_005083 
(ZRSR1)  
BF968097 
 
UGCG AW444934 
 
DNAJB11 AK000847 
 
PDP2 MCM9 ZNF79 
 
H46176 
 
BM849515 ARHGAP24 
 
IFT27 DDR2 
 
GNAL N4BP2L2 ATF3 
 
VAMP2 
 
TPTE IQGAP3 
  
ITGAM 
 
RDH10 DDR2 
  
UIMC1 
 
NM_024914 TEX13A 
  
BTRC 
 
NIP7 BF509796 
  
AI423165 
 
PTPN14 DTNA 
  
IFNA5 
 
CCNB1 ITGAM 
  
TMEM25 
 
AV649908 LOC283070 
  
PCDH9 
 
LINC00032 AI423165 
  
COX8C 
 
AA416756 CCDC82 
  
AI810034 
 
TTF2 AI810034 
  
GOSR2 
 
AW195867 LOC400084 
  
IL17F 
 
FOXN3 PSPC1 
  
SP3 
 
DOCK10 APOBEC3G 
  
ALB 
 
HSPA6 ALB 
  
HAUS5 
 
FBXO4 ZNF79 
  
ZHX2 
 
BC017896 FAM105B 
  
ZNF45 
 
DNM3 AI419968 
  
FAM105B 
 
ARMC8 AI911318 
  
PFKP 
 
ANXA6 BC039439 
  
AI911318 
 
PRR11 AU145323 
  
DEPTOR 
 
LRRC59 HAO1 
  
BE894882 
 
AURKA BC005379 
  
TMCO6 
 
ATP1A3 AA716482 
  
BC005379 
 
TOB1 NPEPL1 
  
C1orf85 
 
BC040701 PDZD2 
  
LOC10028
7616  
AL117451 ALDH8A1 
  
C18orf25 
 
ITGAL T57946 
  
AK074226 
 
AI819238 N53959 
  
HSD17B1 
 
RHOC AL049302 
  
C15orf23 
 
TRIM13 UBR1 
  
KDM1A 
 
AI912723 LGSN 
  
BUB3 
 
SAMD14 AI251890 
  
AEN 
 
BF829112 STYX 
  
SEC61A2 
 
W80619 PCDH7 
  
CHMP6 
 
LIMS1 HIPK3 
  
AK022170 
  
MTHFD2L 
  
CMTM8 
 
SLC24A2 MS4A6E 
  
ZNF703 
  
SLC22A1 
  
NDUFA13 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
NM_000570 AW300131 
  
NM_0186
76   
EIF4E2 
  
POLRMT 
 
BC040304 BC033970 
  
TRIB1 
  
AA442776 
  
NVL 
 
AI809906 W79643 
  
AOC3 
  
AOC3 
  
TP53I13 
 
SLC3A1 TRERF1 
  
WDR96 
  
BF508868 
  
UBR1 
 
AW274257 EGR1 
  
BF508868 
  
WDR96 
  
LEPROT 
 
CYP2C9 RBM34 
  
ORC1 
  
LOC10050608
3   
MTHFD2L 
 
AL137539 RBM25 
  
BE466077 
  
DTL 
  
C7orf45 
 
AK021679 GSN 
  
AF318328 
  
HMOX1 
  
AI033967 
 
AI806127 IGF2BP1 
  
AU159414 
  
BF515913 
  
PGP 
 
GTF2I EXOC3L4 
  
SLC35D2 
  
PFDN6 
  
MRPL4 
 
ITGB1 RGS1 
  
DNAJC14 
  
SRSF5 
  
GAS5 
 
AF113689 AL110176 
  
N32025 
  
TEX14 
  
CCNL2 
 
AL117426 IGLV3-25 
  
AI569997 
  
BE644816 
  
TTC13 
 
FMO1 CPB2 
  
FHDC1 
  
CHORDC1 
  
WDR96 
 
FBN1 SNX24 
  
TEAD2 
  
LOC10050749
5   
AF253979 
 
CCDC30 T86874 
  
EPB41L4B 
  
ZNF473 
  
GLI2 
 
BCL2L10 C11orf57 
  
BF055200 
  
AW132066 
  
LOC1005
06161  
R51853 KRT27 
  
TEX14 
  
AI885066 
  
AV75602
6  
ZFR RFFL 
  
MORF4L2 
  
RBM26-AS1 
  
TMEM12
8  
AF394782 YWHAE 
  
TRIM11 
  
ZNF346 
  
SNAPC4 
 
 
SIRT4 
  
BF740216 
  
AW292905 
  
MSL1 
 
 
VNN3 
  
ID3 
  
DNAH12 
  
UQCR11 
 
    
RBM12 
  
LOC10050704
9   
ATP6AP1L 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
    
LRIF1 
  
AI423466 
  
TEAD2 
 
    
MPP3 
  
HIST1H3H 
  
PPP1R15
A  
    
TLL2 
  
AU144129 
  
BG25650
4  
    
CHORDC1 
  
GNRH1 
  
AL530869 
 
    
CYHR1 
  
HDAC8 
  
SLC4A5 
 
    
CCNB1 
  
ATP5E 
  
NM_0142
21  
    
AI146812 
  
AI939588 
  
ID3 
 
    
AA769100 
  
MYH3 
  
AW29299
6  
    
RBM26-
AS1   
NM_031211 
  
ANGEL2 
 
    
AI885066 
  
FGF18 
  
RBMX 
 
    
LOC72901
3   
ZNF254 
  
BE644816 
 
    
G2E3 
  
AI824013 
  
UGGT1 
 
    
ZIC3 
  
DENND4C 
  
KRTDAP 
 
    
TMEM68 
  
KIAA1432 
  
TNKS2 
 
    
POGZ 
  
ZNF557 
  
CHORDC1 
 
    
AU144129 
  
FSD1L 
  
CYHR1 
 
    
BE299495 
  
AF086424 
  
MARVELD
1  
    
LOC10050
7619   
DDIT4 
  
MEN1 
 
    
AI939588 
  
GTF2H1 
  
PFAS 
 
    
MYH3 
  
GATM 
  
MLEC 
 
    
D59630 
  
GPR83 
  
ND2 
 
    
BC042016 
  
T78087 
  
PURB 
 
    
AGBL3 
  
ABHD12 
  
SUB1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
    
ATR 
  
TSGA10 
  
SLC33A1 
 
    
BF477573 
  
N58120 
  
AI146812 
 
    
NM_0177
61   
SCG5 
  
AI733801 
 
    
LOC10050
5696   
AA503877 
  
SLC25A37 
 
    
PATZ1 
  
ZSCAN30 
  
TRABD 
 
    
AI800419 
  
ABCF2 
  
AA71483
5  
    
FAM110B 
  
R17062 
  
LAMB2 
 
    
AA706701 
  
LRRC37A3 
  
NFX1 
 
    
TSC22D3 
  
L39064 
  
BRAP 
 
    
C7orf42 
  
ACACB 
  
LOC1005
05761  
    
GTSE1 
  
AI863194 
  
NHLH2 
 
    
CDC25C 
  
CCDC11 
  
AU14412
9  
    
DDIT4 
  
C7orf53 
  
MYH3 
 
    
BF057656 
  
PRR14 
  
YPEL5 
 
    
GATM 
  
LOC10050729
7   
AGBL3 
 
    
BF217471 
  
AW117229 
  
SSH2 
 
    
KDM6A 
  
SEPT7P2 
  
AI797678 
 
    
ACP2 
  
AI650407 
  
AA47853
7  
    
RBBP4 
  
TMEM116 
  
TSPAN12 
 
    
CCNL1 
  
SMC1A 
  
FKBP10 
 
    
TSGA10 
  
ACTN2 
  
MAF1 
 
    
SCG5 
  
AA844689 
  
RANGRF 
 
    
BE672818 
  
MEIG1 
  
HBS1L 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
    
ZSCAN30 
  
TPH1 
  
PTBP2 
 
    
BCL2L2 
  
LPXN 
  
COL5A2 
 
    
MID2 
  
AI695695 
  
SIX2 
 
    
PVRL3-
AS1   
LRRC39 
  
RNASET2 
 
    
TMEM138 
  
CDNF 
  
C19orf60 
 
    
HNRNPA1 
  
ID4 
  
PLK2 
 
    
TERF2 
  
AI369073 
  
NUS1 
 
    
TBCE 
  
NEB 
  
GTF2H1 
 
    
AB051480 
  
LARP1B 
  
AA63413
8  
    
C7orf53 
  
TTC18 
  
C20orf11
1  
    
AL832136 
  
BF224430 
  
RARS2 
 
    
AI650407 
  
AI831514 
  
NMNAT1 
 
    
FLJ45482 
  
TTBK2 
  
EPB41L4A
-AS1  
    
AI206345 
  
NM_004038 
  
RBBP4 
 
    
ACTN2 
  
AI809760 
  
RAD23A 
 
    
DIDO1 
  
CDK12 
  
UNK 
 
    
PRKCD 
  
POMZP3 
  
C9orf100 
 
    
H50121 
  
RPP30 
  
AFAP1L2 
 
    
POPDC2 
  
ZFP2 
  
AU15642
1  
  
RGL1 
 
TPH1 
  
LOC81691 
  
ZSCAN30 
 
  
PSMC3IP 
 
ATL2 
  
BE673747 
  
AA50387
7  
  
AU158573 
 
LRRC39 
  
CLEC4A 
  
RAD52 
 
  
CORIN 
 
ADAMTS1 
  
AOC2 
  
SNHG12 
 
  
BTBD11 
 
FLJ31958 
  
EME2 
  
CDCA3 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
CA2 
 
SUDS3 
  
LRRC23 
  
TBRG1 
 
  
PRSS23 
 
INSIG1 
  
AL833615 
  
LOC2850
74  
  
GTPBP3 
 
NEB 
  
SAT1 
  
AKT1 
 
  
ZNFX1-
AS1  
ITPRIPL2 
  
FUBP1 
  
PHF19 
 
  
MLST8 
 
RSRC2 
  
AA331548 
  
PDLIM7 
 
  
ISG20 
 
AI808359 
  
ERP44 
  
SLC39A9 
 
  
TMEM177 
 
PCF11 
  
IREB2 
  
CYP2C19 
 
  
RBM5 
 
BMP7 
  
ZNF846 
  
TM9SF4 
 
  
WDR6 
 
REPIN1 
  
SLC6A13 
  
ZNF264 
 
  
ECEL1 
 
LINC0009
4   
LOC387723 
  
AI768374 
 
  
PRKRIP1 
 
NM_0040
38   
XRN1 
  
AL049314 
 
  
NM_0308
01  
NKTR 
  
ACTA1 
  
PDPK1 
 
  
BF995452 
 
NOP58 
  
PLGLB2 
  
EIF4A2 
 
  
ZNF227 
 
PRR5 
  
LOC645513 
  
PAN3-AS1 
 
  
TMEM74B 
 
CLEC4A 
  
AA142959 
  
C7orf53 
 
  
COG3 
 
DCAF4L1 
  
RFPL3-AS1 
  
UBE2R2 
 
  
BC029614 
 
WDR66 
  
LCA5L 
  
AL832136 
 
  
AL134451 
 
LOC10050
7424   
HIST1H2BD 
  
SNHG6 
 
  
FBXL17 
 
DNAH10 
  
PGAP1 
  
AI650407 
 
  
BG469257 
 
LRRC23 
  
ZNF101 
  
TDH 
 
  
AW87466
9  
AL833615 
  
CTSK 
  
LOC3994
91  
  
CARS 
 
HNRNPU-
AS1   
TTC21B 
  
XPO4 
 
  
NR2C2 
 
FBXO38 
  
W56760 
  
TPH1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
HLA-DQB1 
 
FUBP1 
  
CHD2 
  
PCSK5 
 
  
AA767131 
 
MANBA 
  
HELQ 
  
DPY19L4 
 
  
FAM108A
1  
HIST1H2B
K   
NM_022155 
  
BC043400 
 
  
MAP3K4 
 
NDRG1 
  
CCDC41 
  
DNAJA1 
 
  
GRSF1 
 
CKS2 
  
HOXB-AS3 
  
PRSS30P 
 
  
AA431379 
 
SLC6A13 
  
PIK3C2A 
  
MAP6D1 
 
  
KIAA1468 
 
LOC38772
3   
ACRC 
  
PRDM2 
 
  
RBPMS 
 
XRN1 
  
AA868809 
  
BC000320 
 
  
PRRC2A 
 
ACTA1 
  
TMED6 
  
OR7E14P 
 
  
AI810103 
 
PHF23 
  
AA843122 
  
ATF3 
 
  
NPIP 
 
C14orf101 
  
WDR78 
  
AI692523 
 
  
CROCCP2 
 
RFPL3-
AS1      
AW62767
1  
  
GOLGA1 
 
FAM84B 
     
EIF5 
 
  
UBE2N 
 
PGAP1 
     
PRKAB1 
 
  
C3orf19 
 
PPP1R16A 
     
SQLE 
 
  
H04996 
 
CTSK 
     
SH3YL1 
 
  
HEXIM1 
 
HCLS1 
     
C6orf108 
 
  
GPRASP1 
 
UST 
     
C8orf46 
 
  
AF291676 
 
KANSL1-
AS1      
MDM2 
 
  
PARP11 
 
EFHB 
     
RAD51C 
 
  
WDR67 
 
ZNF33B 
     
KATNB1 
 
  
PAQR4 
 
CTH 
     
DCAF4L1 
 
  
POLH 
 
NM_0221
55      
CLEC4A 
 
  
RC3H2 
 
FAM134A 
     
PARP6 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
BC031948 
 
HEPACAM
2      
BF431313 
 
  
PTGES2 
 
PIK3C2A 
     
ZC3H7A 
 
  
FILIP1L 
 
ACRC 
     
LOC7298
87  
  
ACTB 
 
TMED6 
     
CTNNB1 
 
  
PFN2 
 
AW99325
7      
LRRC23 
 
  
BF968097 
 
C6orf70 
     
RABGAP1 
 
  
H46176 
 
PRC1 
     
FBXO38 
 
  
UIMC1 
 
TRPC1 
     
IER5L 
 
  
TMEM25 
 
HSPH1 
     
KIAA0753 
 
  
COX8C 
 
IDI2-AS1 
     
FBXO5 
 
  
GOSR2 
 
AA843122 
     
ZNF654 
 
  
SP3 
 
LEFTY1 
     
TRA2B 
 
  
HAUS5 
 
WDR78 
     
STIL 
 
  
DEPTOR 
       
SLC25A4 
 
  
C18orf25 
       
SLFN5 
 
  
KDM1A 
       
POP5 
 
  
CHMP6 
       
LOC1005
07670  
  
NDUFA13 
       
C6orf48 
 
  
POLRMT 
       
ARMCX5 
 
  
TP53I13 
       
ZNF217 
 
  
NVL 
       
DHPS 
 
  
LEPROT 
       
OVOS2 
 
  
CCNL2 
       
SLC6A13 
 
  
TTC13 
       
KANSL1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
AF253979 
       
FAM53C 
 
  
GLI2 
       
AL109698 
 
  
LOC10050
6161        
ACTA1 
 
  
TMEM128 
       
SNX5 
 
  
SNAPC4 
       
ZNF706 
 
  
ATP6AP1L 
       
EEF1D 
 
  
SLC4A5 
       
VPS33B 
 
  
ANGEL2 
       
TBX1 
 
  
RBMX 
       
RFPL3-
AS1  
  
TNKS2 
       
NDST2 
 
  
KRTDAP 
       
HIST1H2B
D  
  
MARVELD
1        
PGAP1 
 
  
MLEC 
       
SLC7A6OS 
 
  
PURB 
       
AA86850
0  
  
SUB1 
       
ZNF101 
 
  
AI733801 
       
CTSK 
 
  
LAMB2 
       
AL110133 
 
  
NFX1 
       
EFHB 
 
  
NHLH2 
       
CHD2 
 
  
LOC10050
5761        
RBM15B 
 
  
YPEL5 
       
AC00204
5  
  
AI797678 
       
EIF2C3 
 
  
AA478537 
       
ACRC 
 
Table S3, page 10 
 
Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
FKBP10 
       
CHDH 
 
  
HBS1L 
       
LOC1002
88637  
  
RANGRF 
       
TMED6 
 
  
PTBP2 
       
CATSPER
D  
  
COL5A2 
       
TUB 
 
  
SIX2 
       
DEDD2 
 
  
RNASET2 
       
PLEKHG4 
 
  
C19orf60 
       
AI638235 
 
  
RARS2 
       
WDR78 
 
  
UNK 
       
TYW5 
 
  
C9orf100 
       
BOP1 
 
  
AU156421 
       
DDIT3 
 
  
RAD52 
       
SPRN 
 
  
SNHG12 
       
AI692591 
 
  
TBRG1 
       
MCM9 
 
  
LOC28507
4        
C1orf216 
 
  
AKT1 
       
N4BP2L2 
 
  
PHF19 
       
DDR2 
 
  
SLC39A9 
       
MCAM 
 
  
TM9SF4 
       
GDPD3 
 
  
HSPA6 
       
PTK2 
 
  
ZNF264 
       
LOC1005
06606  
  
AI768374 
       
MYCBP2 
 
  
PDPK1 
       
AI810034 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
EIF4A2 
       
WIZ 
 
  
SNHG6 
       
ACTA2 
 
  
TDH 
       
PSPC1 
 
  
LOC39949
1        
C20orf72 
 
  
XPO4 
       
LINC0026
3  
  
PCSK5 
       
NM_0053
45  
  
DPY19L4 
       
NM_0035
16  
  
DNAJA1 
       
SPRYD4 
 
  
PRSS30P 
       
BC005379 
 
  
MAP6D1 
       
NPEPL1 
 
  
PRKAB1 
       
ALDH8A1 
 
  
SQLE 
       
U62733 
 
  
RAD51C 
       
BF221525 
 
  
PARP6 
       
CLMN 
 
  
CTNNB1 
       
FAHD2A 
 
  
RABGAP1 
       
CKB 
 
  
KIAA0753 
       
ENSA 
 
  
FBXO5 
       
AL831886 
 
  
IER5L 
       
BM35314
2  
  
ZNF654 
       
PCDH7 
 
  
SLFN5 
       
POLD3 
 
  
POP5 
       
PPP1R10 
 
  
LOC10050
7670        
HOXC6 
 
  
C6orf48 
       
TRIB1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
ZNF217 
       
ZNF551 
 
  
OVOS2 
       
ARHGAP2
6  
  
KANSL1 
       
TMEM48 
 
  
FAM53C 
       
AF271775 
 
  
AL109698 
       
SLC13A3 
 
  
VPS33B 
       
KIAA1324 
 
  
TBX1 
       
BF593636 
 
  
SLC7A6OS 
       
W58255 
 
  
AL110133 
       
CENPN 
 
  
RBM15B 
       
CPLX1 
 
  
EIF2C3 
       
KLF10 
 
  
AC002045 
       
PFDN6 
 
  
CATSPERD 
       
AI610347 
 
  
LOC10028
8637        
SRSF5 
 
  
CHDH 
       
WDR13 
 
  
TUB 
       
TEX14 
 
  
DEDD2 
       
QTRT1 
 
  
AI692591 
       
TRIM11 
 
  
MCAM 
       
PSME3 
 
  
ACTA2 
       
SEC31B 
 
  
C20orf72 
       
TMEM50
B  
  
LINC0026
3        
ERI2 
 
  
NM_0053
45        
NXF1 
 
  
BF221525 
       
NME3 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
CLMN 
       
RIOK3 
 
  
AL831886 
       
NSUN5P1 
 
  
BM35314
2        
RBM26-
AS1  
  
POLD3 
       
ZNF346 
 
  
PPP1R10 
       
ARL17A 
 
  
HOXC6 
       
RBM25 
 
  
ZNF551 
       
NM_0050
83  
  
ARHGAP2
6        
LOC4411
24  
  
TMEM48 
       
SLC27A4 
 
  
AF271775 
       
MACROD
2  
  
SLC13A3 
       
DPAGT1 
 
  
CENPN 
       
FAM127A 
 
  
KLF10 
       
PPPDE2 
 
  
WDR13 
       
METTL3 
 
  
PSME3 
       
HDAC8 
 
  
ERI2 
       
EPC1 
 
  
NXF1 
       
NCDN 
 
  
NME3 
       
TMEM80 
 
  
RIOK3 
       
C7orf61 
 
  
NSUN5P1 
       
ZNF589 
 
  
ARL17A 
       
AI939588 
 
  
LOC44112
4        
RUFY1 
 
  
MACROD
2        
LOC2021
81  
  
DPAGT1 
       
AF339807 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
FAM127A 
       
TRA2A 
 
  
PPPDE2 
       
PP7080 
 
  
METTL3 
       
LPCAT4 
 
  
EPC1 
       
YTHDC1 
 
  
TMEM80 
       
SGSM3 
 
  
RUFY1 
       
PPP1R3E 
 
  
YTHDC1 
       
PRKXP1 
 
  
SGSM3 
       
LDOC1 
 
  
PRKXP1 
       
GPR19 
 
  
LDOC1 
       
FGF18 
 
  
KDM3A 
       
KDM3A 
 
  
AI356405 
       
AA50744
2  
  
C22orf23 
       
NAV1 
 
  
MYO1D 
       
AI356405 
 
  
MIEN1 
       
C22orf23 
 
  
SNX14 
       
RGL1 
 
  
ARFIP2 
       
DNAJC27 
 
  
BM97030
6        
TSC22D3 
 
  
E2F7 
       
MYO1D 
 
  
GTF3C2 
       
MIEN1 
 
  
C15orf17 
       
SNX14 
 
  
WAC 
       
PSMC3IP 
 
  
AW02868
7        
ARFIP2 
 
  
GPD1L 
       
AU15857
3  
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
RPL37 
       
CORIN 
 
  
IFRD1 
       
BTBD11 
 
  
NCOA4 
       
KDM6A 
 
  
BM68205
7        
CA2 
 
  
LRRC14 
       
BM97030
6  
  
UBR4 
       
E2F7 
 
  
ITIH4 
       
PRSS23 
 
  
MAPK1IP1
L        
GTPBP3 
 
  
TXNIP 
       
ZNFX1-
AS1  
  
ZNF776 
       
GTF3C2 
 
  
SF3B3 
       
SCG5 
 
  
FAM125A 
       
MLST8 
 
  
FAF2 
       
C15orf17 
 
  
SPATA7 
       
ISG20 
 
  
T71642 
       
ABCF2 
 
  
NSUN5P2 
       
TMEM17
7  
  
LRIG2 
       
RBM5 
 
  
C1orf162 
       
R17062 
 
  
AA042983 
       
WAC 
 
  
TMEM206 
       
AI863194 
 
  
AC003007 
       
WDR6 
 
  
HEATR1 
       
AW02868
7  
  
VPS8 
       
GPD1L 
 
  
GCDH 
       
HNRNPA1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
  
MMP24 
       
RPL37 
 
  
C16orf53 
       
IFRD1 
 
  
LOC44089
4        
NCOA4 
 
  
TMEM100 
       
BM68205
7  
  
LOC44099
3        
ECEL1 
 
  
ZNF200 
       
LRRC14 
 
  
BC038430 
       
UBR4 
 
  
GBA2 
       
PRKRIP1 
 
  
MFSD3 
       
ZNF79 
 
  
AA973551 
       
NM_0308
01  
  
AI792670 
       
AW11722
9  
  
PCIF1 
       
SEPT7P2 
 
  
LOC10050
6713        
BF995452 
 
    NAT14         
   
ITIH4 
 
          
MAPK1IP
1L  
          
TXNIP 
 
          
SMC1A 
 
          
ZNF776 
 
          
SF3B3 
 
          
ZNF227 
 
          
FAM125A 
 
          
TMEM74
B  
          
FAF2 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
          
POPDC2 
 
          
COG3 
 
          
LPXN 
 
          
LRRC39 
 
          
BC029614 
 
          
AL134451 
 
          
FBXL17 
 
          
SPATA7 
 
          
BG46925
7  
          
NEB 
 
          
TTC18 
 
          
T71642 
 
          
NSUN5P2 
 
          
LRIG2 
 
          
C1orf162 
 
          
AW87466
9  
          
CARS 
 
          
NR2C2 
 
          
NM_0040
38  
          
AA04298
3  
          
HLA-
DQB1  
          
TMEM20
6  
          
AC00300
7  
          
HEATR1 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
          
AL833615 
 
          
AA76713
1  
          
VPS8 
 
          
FUBP1 
 
          
FAM108A
1  
          
MAP3K4 
 
          
GCDH 
 
          
MMP24 
 
          
ZNF846 
 
          
IREB2 
 
          
C16orf53 
 
          
GRSF1 
 
          
AA43137
9  
          
LOC4408
94  
          
TMEM10
0  
          
KIAA1468 
 
          
C14orf10
1  
          
LOC6455
13  
          
LOC4409
93  
          
FAM84B 
 
          
RBPMS 
 
          
ZNF200 
 
          
PRRC2A 
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
          
AI810103 
 
          
NPIP 
 
          
CROCCP2 
 
          
GOLGA1 
 
          
BC038430 
 
          
UBE2N 
 
          
GBA2 
 
          
C3orf19 
 
          
NM_0221
55  
          
MFSD3 
 
          
H04996 
 
          
AA97355
1  
          
HEXIM1 
 
          
PIK3C2A 
 
          
GPRASP1 
 
          
AI792670 
 
          
PCIF1 
 
          
AF291676 
 
          
PARP11 
 
          
LOC1005
06713  
          
WDR67 
 
          
PAQR4 
 
          
POLH 
 
          
RC3H2 
 
          
AA84312
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Table S3. Genes that overlap at each timepoint between two DNA carriers (PEI and LF2000) (from Figure 4). 
2 h time point 8 h time point 16 h time point 24 h time point 
LF2000 
(44 genes) 
PEI 
(46 genes) 
LF2000 U 
PEI 
(0 genes)1 
LF2000 
(5 genes) 
PEI 
(177 
genes) 
LF2000 U PEI 
(2 genes) 1 
LF2000 
(22 genes) 
PEI 
(151 genes) 
LF2000 U PEI 
(5 genes) 1 
LF2000 
(0 genes) 
PEI 
(454) 
LF2000 U 
PEI 
(2 genes) 1 
2 
          
BC031948 
 
          
PTGES2 
 
          
NAT14 
 
          
FILIP1L 
 
1U stands for the union of the time points, e.g. a gene that was found at multiple time points. 
 
